

REFERENCES FOR DRUG DOSAGE GUIDELINES FOR INFANTS AND OLDER CHILDREN

1. Hughes HK et al (eds) *The Harriet Lane Handbook—21st edition*. Elsevier Inc 2017
2. Barst RJ et al. A randomized, double blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment naïve children with pulmonary arterial hypertension. *Circulation* 2012; 125 (2): 324-334
3. Hayashi AH et al Topical sucralfate: effective therapy for the management of resistant peristomal and perineal excoriation. *J Pediatr Surg* 1991 ; 26(11) : 1279-81.
4. Jovaisas B (ed) *Compendium of Pharmaceuticals and Specialties (CPS)—43rd Edition*. Ottawa: Canadian Pharmaceutical Association; 2015.
5. Bradley JS (ed). *Nelson's Pediatric Antimicrobial Therapy--20th Edition*. American Academy of Pediatrics. 2014.
6. American Academy of Pediatrics. Kimberlin DW, Barnett ED, Lynfield R eds. 2021 Red Book Report of the Committee on Infectious Diseases—32nd Edition. Elk Grove Village IL: 2021
7. Hämäläinen ML, Hoppu K, Santavuori P. Sumatriptan for migraine attacks in children: a randomized placebo-controlled study. Do children with migraine respond to oral sumatriptan differently from adults? *Neurology*. 1997 Apr;48(4):1100-3.
8. Schoot RA, van Dalen EC, van Ommen CH et al. Antibiotic and other lock treatments for tunneled central venous catheter-related infections in children with cancer. *Cochrane Database of Systematic Reviews* 2013 Issue 6. Art No. CD008975
9. Aronoff GR, Bennett WM (eds) *Drug Prescribing in Renal Failure*, 5th edition 2007. American College of Physicians.
10. Tighe M et al. Pharmacological treatment of children with gastro-oesophageal reflux. *Cochran Database Syst Rev*. 2014 Nov 24.
11. Metzger D. BCCH Endocrine Handout: Adrenal Steroid Therapy and Weaning. Oct 2009.<http://www.bcchildrens.ca/Services/SpecializedPediatrics/EndocrinologyDiabetesUnit/ForProfessionals/Handouts.htm#endocrine>
12. Choong C, Kisson N. Vasopressin in pediatric shock and cardiac arrest. *Pediatr Crit Care Med* 2008; 9:372-9.
13. Kim SY et al. Intravenous pentamidine is effective as second line *Pneumocystis pneumonia* prophylaxis in pediatric oncology patients. *Pediatr Blood Cancer* 2008; 50: 779-783.
14. Vondracek P et al. Efficacy of pregabalin in neuropathic pain in paediatric oncological patients. *Eur J Paediatr Neurol* 2009; 13(4): 332-6.
15. Saul JP et al. Intravenous Amiodarone for Incessant Tachyarrhythmias in Children. A Randomized, Double-Blind, Antiarrhythmic Drug Trial *Circulation*. 2005;112:3470-3477
16. Druka D et al. Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis. *Journal of Cystic Fibrosis* 2008;7:457–459
17. Money D, Tulloch K, Boucoiran I et al. BC Guidelines for care of HIV positive pregnant women and interventions to reduce perinatal transmission. 2013 Available from: <http://www.bcwomens.ca/health-professionals/professional-resources/hiv-aids-resources>
18. Jan JE et al. Melatonin therapy of pediatric sleep disorders: recent advances, why it works, who are the candidates and how to treat. *Curr Pediatr Rev* 2007; 3: 21-224.
19. *Poison Management Manual July 2020*. B.C. Drug and Poison Information Centre, Vancouver; www.dpic.org
20. Glorieux FH. Osteogenesis Imperfecta. *Best Pract Res Clin Rheumatol* 2008. Mar;22(1): 85-100.
21. Li, BU, Lefevre F. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition consensus statement on the diagnosis and management of cyclic vomiting syndrome. *J. Pediatr Gastroenterol Nutr* 2008 Sep; 47(3): 379-93.
22. CATMAT malaria guidelines. Chapter 7-Treatment of malaria: Canadian recommendations for the prevention and treatment of malaria. Updated 2019. Accessed Apr 28, 2022 <https://www.canada.ca/en/public-health/services/catmat/canadian-recommendations-prevention-treatment-malaria.html>

23. Hamida FB et al. Long-term (6 months) cross-over comparison of calcium acetate with calcium carbonate as phosphate binder. *Nephron* 1993; 63: 258-262.
24. Jongerius PH et al. Effect of botulinum toxin in the treatment of drooling: A controlled clinical trial. *Pediatrics* 2004; 114:620-7.
25. O'Brien L et al. A critical review of topical local anesthetic amethocaine (Ametop) for pediatric pain. *Pediatr Drugs* 2005; 7: 41-54.
26. Antiviral Medications for Pandemic (H1N1) 2009 Influenza: Frequently Asked Questions for Health Professionals. Published by Pharmaceutical Services Division of B.C. Ministry of Health Services. Sept 18 2009
27. Koletzko S et al. Evidence-Based Guidelines from ESPGHAN and NASPGHAN for Helicobacter pylori Infection in Children. *J Pediatr Gastroenterol Nutr*, 2011, 53(2):230-43.
28. Hanly JG, Fitzgerald MX. Meconium ileus equivalent in older patients with cystic fibrosis. *Br Med J* 1983; 286: 1411.
29. Seiklay MG. Hypertension in children. An update on treatment strategies. *Current Opinion in Pediatrics* 2007; 19: 170-177.
30. Yang C and Montgomery M. Dornase alfa for cystic fibrosis. *Cochrane Database Syst Rev*. 2021 Mar 18;3(3):CD001127. doi 10.1002/14651858.CD001127.pub5.
31. Adelson PD, Bratton SL, Carney NA et al. Guidelines for the acute medical management of severe traumatic brain injury in infants, children, and adolescents. Chapter 11. Use of hyperosmolar therapy in the management of severe pediatric traumatic brain injury. *Pediatr Crit Care Med* 2003;4:S40-44
32. Personal communications with relevant Medical Department and Division Heads, BCCH
33. Hassall E. et al. Omeprazole for treatment of chronic erosive esophagitis in children: A multicenter study of efficacy, safety, tolerability and dose requirements. *J Pediatr*. 2000; 137: 800-7.
34. Dawkins TN et al. Safety of intravenous use of ketorolac in infants following cardiothoracic surgery. *Cardiol Young* 2009; 19:150-108.
35. Olivieri NF et al. Iron-chelating therapy and the treatment of thalassemia. *Blood* 1997; 89 (3): 739-761.
36. Committee on Nutrition. Aluminum Toxicity in Infants and Children. *Pediatrics* 1996; 97(3): 413-416
37. de Caen AR, Berg MD, Chameides L et al. Part 12: Pediatric Advanced Life Support 2015 AHA Guidelines for Cardiopulmonary Resuscitation and Emergency cardiovascular care. *Circulation* 2015;132 (Suppl 2) S526-42
38. Koczmarc C et al. Meperidine (Demerol) safety issues. *Dynamics (Journal of Canadian Assoc of Critical Care Nurses)* 2005;16(1): 8-12
39. Durkan AM et al. The use of darbepoetin in infants with chronic renal impairment. *Pediatr Nephrol* 2006; 21: 694-7.
40. Cies JJ, Giamalis JN. Treatment of cholestatic pruritus in children. *Am J Health-Syst Pharm* 2007;64:1157-62
41. Yoshikawa N, Nakanishi K et al. A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment. *Kidney Int* 015; 87: 225-232
42. Maladi P, Koren G. Pharmacogenetic insights into codeine analgesia: implications to pediatric codeine use. *Pharmacogenetics* 2008; 9(9): 1267-84.
43. Strahlendorf C. Optimizing peripheral stem cell mobilization and harvest in very small children. *J Clin Apheresis* 2005; 20: 63-64.
44. Taketomo C (ed). *Pediatric Dosage Handbook*. 28th edition. Lexi Comp Inc. Cleveland; 2021.
45. Brunner HI et al. Pediatric SLE—towards a comprehensive management plan. *Nature Reviews Rheumatology* 2011. 7(4): 225-233.
46. Stockmann C, Sherwin CMT, Zobell JT et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III Fluoroquinolones. *Pediatr Pulmonol* 2013;48:2011-20.
47. Lerner G et al. Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease. *Pediatr Nephrol* 2002; 17: 933-7.
48. BCCH Algorithm for Croup in the Emergency Department March, 2012.

49. James PJ et al. The addition of ketamine to a morphine nurse-or patient-controlled analgesia infusion (PCA/NCA) increases analgesic efficacy in children with mucositis pain. *Pediatr Anesthes* 2010; 20: 805-11.
50. Rowland AG et al. Review of the efficacy of rectal paraldehyde in the management of acute and prolonged tonic-clonic convulsions. *Arch Dis Child* 2009; 94: 720-723.
51. Croup: Pharmacologic and Supportive Interventions. UpToDate. Online access November 18, 2021
52. Laer S et al. Development of a safe and effective pediatric dosing regimen based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia. *J Am Coll Cardiol* 2005; 46:1322-30.
53. Vander Bijl P et al. Disinhibitory reactions to benzodiazepines: A review. *J Oral Maxillofac Surg* 1991; 49: 519-523.
54. Child Health BC. Provincial Asthma Guideline; Initial Management of Pediatric Asthma in Emergent/Urgent Care Settings. Vancouver, BC: Child Health BC, April 2018
55. Walsh EP et al. Evaluation of a Staged Treatment Protocol for Rapid Automatic Junctional Tachycardia After Operation for Congenital Heart Disease. *J Am Coll Cardiol* 1997;29: 1046 –53.
56. Cole TS, Riordan A. Vancomycin dosing in children: what is the question? *Arch Dis Child* 2013;98:994-7.
57. Greenhill L, Kollins S, Abikoff H et al. Efficacy and Safety of Immediate-Release Methylphenidate Treatment for Preschoolers with ADHD. *J Am Acad Child Adolesc Psychiatry* 2006; 45: 1284-93.
58. Ng E et al. Guidelines for vitamin K prophylaxis in newborns. Canadian Pediatric Society Position Statement. *Paediatr Child Health* 2018;23:394-7
59. Clark MB et al. American Academy of Pediatrics: Clinical Report: Fluoride Use in Caries Prevention in the Primary Care Setting. *Pediatrics*, December 2020, Vol 136 (6); e2020034637
60. Ferguson MA, Flynn JT. Rational use of antihypertensive medication in children. *Pediatr Nephrol* 2013; 29(3): 979-988.
61. Haberle et al. Suggested Guidelines for the diagnosis and management of urea cycle disorders. *Orphanet Journal of Rare Diseases* 2012;7:32
62. Lallas M et al. Wernicke encephalopathy in children and adolescents. *World J Pediatr* 2014; 10 (4): 293-8.
63. <http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2000/14309a-eng.php> (Cisapride warning)
64. Sathe MN, Patel AS. Update in pediatrics: Focus on fat-soluble vitamins. *Nutrition in Clinical Practice*. 2010; 25(4): 340-346.
65. Bruns L.A. et al. Should β blockers be used for the chronic treatment of pediatric patients with chronic heart failure. *Pediatric Drugs* 2002; 4(12): 771-778
66. Ostman-Smith I et al. A Cohort study of childhood Hypertrophic Cardiomyopathy. *Journal of American Coll Cardiol* . 1999: 34(6) 1813-1822.
67. Manufacturer's literature.
68. Walsh TJ et al. Pharmacokinetics, safety and tolerability of caspofungin in children and adolescents. *Antimicrob Agents Chemother* 2005; 49(11): 4536-45.
69. Chrysostomou C et al. Dexmedetomidine use in a pediatric intensive care unit: Can we use it in infants after cardiac surgery: *Pediatr Crit Care Med* 2009; 10: 654-660.
70. Van Eyk, N et al Pediatric Vulvovaginal disorders: A diagnostic approach and review of the literature. *J Obstet Gynaecol Can* 2009; 31(9): 850-862.
71. Van Karnebeek, C. et al. Current Treatment and Management of Pyridoxine-Dependent Epilepsy. *Curr Treat Options Neurol* 2015. 17 (2): 335
72. Penack O, Marchett M, Ruutu T et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. *Lancet Haematol* 2020;7:e157-67
73. Equi A et al. Long term azithromycin in children with cystic fibrosis : a randomised, placebo controlled crossover trial. *Lancet* 2002 : 360 : 978-84.
74. Scheinberg P, Nunez O, Weinstein B et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. *New Engl J Med* 2011;365:430-8

75. Ettenger R et al. Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients. *Pediatric Transplantation* 2005 ;9 : 780-7.
76. Adefurin A, Sammons H, Jacqz-Aigrain E et al. Ciprofloxacin safety in paediatrics: a systematic review. *Arch Dis Child* 2011;96:874-80
77. Lee SH et al. Minimal effective dosage of recombinant human erythropoietin in spinal surgery. *Clin Orthop* 2003; 412: 71-6.
78. Alper A et al. Polyethylene glycol: A game-changer laxative for children. *JPGN* 2013; 57: 134-140.
79. Evans, D et al. Intravenous ketamine sedation for painful oncology procedures. *Pediatr Anesthesia* 2005; 15(2): 131-138.
80. Zimmermann AE et al. A review of omeprazole use in the treatment of acid-related disorders in children. *Clin Ther* 2001;23(5):660-79.
81. Chan HS et al. Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: double-blind, crossover trial. *Pediatrics* 1987; 79(6): 946-52.
82. Fischer JH, Patel TV, Fischer PA. Fosphenytoin. *Clinical Pharmacokinetics and Comparative Advantages in the Acute Treatment of Seizures. Clin Pharmacokinet* 2003;42(1):33-58
83. Elbe D, Black TR, McGrane IR, Procyshyn RM (eds) 2019. *Clinical Handbook of Psychotropic Drugs for Children and Adolescents -4th ed.* Boston MA: Hogrefe Publishing
84. Carr R et al. Long-term effectiveness outcome of melatonin therapy in children with treatment-resistant circadian rhythm sleep disorders. *J Pineal Res* 2007 ; 3 :351-59.
85. Flynn JT et al. Population pharmacokinetics of amlodipine in hypertensive children and adolescents. *J Clin Pharmacol* 2006; 46: 905-916.
86. Schulte PFJ. Risk of Clozapine-Associated Agranulocytosis and Mandatory White Blood Cell Monitoring. *Ann Pharmacother* 2006; 40; 683-8.
87. Grond S et al. Clinical pharmacology of tramadol. *Clin Pharmacokinet* 2004; 43(13): 879-923.
88. Walker J et al. Sedation using dexmedetomidine in pediatric burn patients. *J Burn Care Res* 2006; 27: 206-10
89. Thomas J et al. Treatment of Aspergillosis : Clinical Practice Guidelines of the Infectious Diseases Society of America. *CID* 2008; 46: 327-360.
90. Monagle P et al. Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: ACCP evidence-based clinical practice guidelines. *Chest* 2012; 141: e737S-e801S.
91. Godel JC. Canadian Paediatric Society Position Statement. Vitamin D supplementation: Recommendations for Canadian mothers and infants. *Paediatr Child Health* 2007;12(7):583-9(reaffirmed Jan 30, 2015))
92. Carr RR et al. Azithromycin for improving pulmonary function in cystic fibrosis. *Ann Pharmacother* 2004; 38: 1520-4.
93. Pappas PG, Kauffman CA, Andes DR et al. Clinical practice guidelines for the management of candidiasis: 2016 Update by the Infectious Diseases Society of America. *CID* 2016;62:e1-50
94. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. *Br J Psychiatry.* 2009 Jan; 194(1):4-9.
95. Ketter TA, Wang PW, Chandler RA et al. Dermatology precautions and slower titration yield a low incidence of lamotrigine treatment emergent rash. *J Clin Psychiatry* 2005; 66: 642-5.
96. Bozkurt P. Use of tramadol in children. *Pediatric Anaesthesia* 2005; 15: 1041-7.
97. Nyhan WL. Treatment of the Acute Crisis in Maple Syrup Urine Disease. *Arch Pediatr Adolesc Med.* 1998;152:593-598
98. National Asthma Council Australia. *Australian Asthma Handbook, Version 2.1.* National Asthma Council Australia, Melbourne, 2020. (www.asthmahandbook.org.au)
99. Zuppa AF et al. Population pharmacokinetics of ketorolac in neonates and young infants. *Am J Ther* 2009; 16(20): 143-6
100. Kimberlin DW et al. Valganciclovir for symptomatic congenital cytomegalovirus disease. *N Engl J Med* 2015 Mar 5; 372(10): 933-43.
101. Hazell P, O'Connell D, Heathcote D, Henry D. Tricyclic drugs for depression in children and adolescents. *Cochrane Database Syst Rev.* 2002;(2):CD002317.

102. Van harten J et al. Negligible sublingual absorption of nifedipine. *Lancet* 1987; Dec 12: 1363-4
103. Murphy JV et al. Deaths in young children receiving nitrazepam. *J Pediatr* 1987; 111 (1): 145-7.
104. Nurko S et al. PEG3350 in the treatment of childhood constipation: a multicenter, double-blinded, placebo-controlled trial. *J Pediatr* 2008; 153: 254-61.
105. Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. *Pediatrics*. 2017;140
106. Flynn JT et al. Efficacy and safety of prolonged amlodipine treatment in hypertensive children. *Pediatr Nephrol* 2005; 20:631-635
107. Standing, J. F., Tibboel, D., Korpela, R. and Olkkola, K. T. (2011), Diclofenac pharmacokinetic meta-analysis and dose recommendations for surgical pain in children aged 1–12 years. *Pediatric Anesthesia* 2011; 21: 316–324.
108. Rose JB et al. Oral tramadol for the treatment of pain of 7-30 days' duration in children. *Anesth Analg* 2003; 96: 78-81
109. Gordillo R et al. The Nephrotic Syndrome. *Pediatr Rev* 2009; 30:94-105.
110. Batshaw ML et al. Alternative pathway therapy for urea cycle disorders: twenty years later. *J Pediatr* 2001; 138:S46-S55.
111. Gillette P, Garson A (eds) *Clinical Pediatric Arrhythmias 2nd Ed.* Philadelphia: WB Saunders: 1999.
112. Micromedex. Thomson Healthcare 2022
113. Mantadakis E. Advances in pediatric intravenous iron therapy. *Pediatr Blood Cancer* 2016;63:11–16
114. Nakamura A et al. Effects of elevated tacrolimus trough levels in association with infectious enteritis on graft function in renal transplant recipients. *Transplant Proc* 2014; 4(2): 592-4.
115. Wuhl E et al. Strict blood pressure control and progression to end stage renal failure in children. *NEJM* 2009; 361(17); 1639-1650.
116. Jones GL, Will A, Jackson GH et al. Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. *Br J Haematol* 2015; 169: 661-671
117. Young, G et al. Argatroban therapy in pediatric patients requiring non heparin anti-coagulation: An open-label safety, efficacy and pharmacokinetic study. *Pediatr Blood Cancer* 2011; 56: 1103-09.
118. Carbaglu product monograph; provided by Orphan Europe.
119. Ramamoorthy C et al. Pharmacokinetics and side effects of milrinone in infants and children after open heart surgery. *Pediatr Anesthesia* 1998; 86:283-9.
120. Kane JM, Leucht S, Carpenter D, Docherty JP. Optimizing Pharmacological treatment of psychotic disorders. *Journal of Clinical Psychiatry* 2003; 64 Suppl 12; 28.
121. Burks C et al. Meperidine for the treatment of shaking chills and fever. *Arch Intern Med* 1980. 140: 483-4.
122. Madabushie R et al . Pharmacokinetic and pharmacodynamic basis for effective argatroban dosing in pediatrics. *J Clin Pharmacol* 2011; 51: 19-28
123. Condren et al. The Emerging Role of Hypertonic Saline in Cystic Fibrosis-Related Pulmonary Disease. *J Pediatr Pharmacol Ther* 2007; 12: 23-30.
124. Deeks ED et al. Rabbit anti-thymocyte globulin (Thymoglobuline): a review of its use in the prevention and treatment of acute allograft rejection. *Drugs* 2009; 69 (11): 1483-1512.
125. Deeg HJ et al. Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. *Biol Blood Marrow Transplant* 2006; 12(5): 573-84.
126. Gao et al. United States Patent. Stable epinephrine suspension formulation with high inhalation delivery efficiency. Amphastar Pharmaceuticals, Feb 5, 2013. #US 8367734B1
127. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2021. Available from: [www. Ginaasthma.org](http://www.Ginaasthma.org)
128. Malignant Hyperthermia Association of the United states: www.mhaus.org
129. Youngster I, Arcavi L, Schechmaster R et al. Medications and glucose-6-phosphate dehydrogenase deficiency. An evidence-based review. *Drug Saf* 2010;33:713-26.
130. Salvadori M, Price V. Preventing and treating infections in children with asplenia or hyposplenia. Canadian Paediatric Society Infectious Diseases and Immunizations Committee. *Paediatr Child*

- Health. Nov 6, 2019 <https://cps.ca/documents/position/preventing-treating-infections-in-children-with-asplenia> [accessed Apr 11, 2022]
131. Borowitz D et al. Consensus report on nutrition for pediatric patients with cystic fibrosis. *J Pediatr Gastroenterol Nutr* 2002; 35(3):246-59.
 132. Goldman RD. Codeine for acute cough in children. *Can Fam Physician* 2010; 56(12): 1293-4.
 133. Health Canada Guidance Document: Non-prescription Oral Paediatric the labelling of Cough and Cold Labelling Standard. 2009
 134. Kitai I, Demers A-M. *Canadian Tuberculosis Standards 7th Edition*. 2014. Chapter 9: Pediatric Tuberculosis
 135. Managing the paediatric patient with an acute asthma exacerbation. Ortiz-Alvarez O et al; Canadian Paediatric Society, Acute Care Committee. *Paediatr Child Health* 2012; 17(5): 251-5. Reaffirmed: Jan 30, 2017
 136. SOGC Clinical Practice Guidelines. Canadian Contraception Consensus, Chapter 3: Emergency Contraception. *J Obstet Gynaecol Can* 2015; 37 (10): S20-28
 137. Vaudry W et al. Valganciclovir dosing according to body surface area and renal function in paediatric solid organ transplantation recipients. *Am J Transplant* 2009; 9: 636-43.
 138. Cassidy JT, Petty RE et al (eds). *Textbook of Pediatric Rheumatology 7th edition*. Philadelphia: Elsevier Saunders: 2016.
 139. Wong LS et al. Potential for methotrexate exposure through contamination during parenteral use as an immunosuppressant. *Internal Medicine Journal* 2009; 39: 379-83.
 140. Monagle P et al (eds). *Andrew's Pediatric Thromboembolism and Stroke*. 3rd ed. 2006; BC Decker Inc. Hamilton
 141. Severin PN et al. The Pediatric Cardiology Pharmacopoeia:2013 Update. *Pediatr Cardiol* 2013; 34: 1-29
 142. Gralla RJ et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. *J Clin Oncol* 1999; 17: 2971-94. metoclopramide
 143. Canadian Paediatric and Adolescent Gynaecology and Obstetricians (CANPAGO) Committee. SOGC Clinical Practice Guideline No. 313-Menstrual Suppression in Special Circumstances. *J Obstet Gynaecol Can* 2019;41(2):e7–e17
 144. Foerster SR et al. Pediatric Heart Failure Therapy with β -Adrenoceptor Antagonists. *Pediatr Drugs* 2008; 10(2): 125-134
 145. Corman SL et al. Atomoxetine: The first non-stimulant for the management of ADHD. *Am J Health Sys Pharm* 2004; 16: 2391-2399.
 146. Giland LS et al. Atomoxetine for the treatment of attention deficit hyperactivity disorder. *Ann Pharmacother* 2004; 38: 86-89.
 147. Haymond MW et al. Mini-dose glucagon rescue for hypoglycaemia in children with type 1 diabetes. *Diabetes Care* 2001; 24(4): 643-5.
 148. Di Iorgi N, Napoli F, Allegri A et al. Diabetes insipidus- Diagnosis and management. *Horm Res Paediatr* 2012;77:69-84
 149. Giglia TM et al. Prevention and treatment of thrombosis in pediatric congenital heart disease. Scientific statement of AHA. *Circulation* 2013; 128: 2611-2703.
 150. Liu C, Bayer A, Cosgrove SE et al. Clinical Practice Guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant *Staphylococcus aureus* infections in adults and children. *Clin Infect Dis* 2011;52:e18-55
 151. Summar M. Current strategies for the management of neonatal urea cycle disorders. *J Pediatr* 2001; 138: S30-S39.
 152. Crandall WV et al. Infusion reaction to infliximab in children and adolescents: frequency, outcome and predictive model. *Aliment Pharmacol Ther* 2003; 17: 75-84.
 153. Martin-Johnston MK et al. Therapeutic amenorrhea in patients at risk for thrombocytopenia. *Obstet Gynecol Surv* 2008; 63(6): 395-402
 154. Ormrod D et al. Topiramate: A review of its use in childhood epilepsy. *Pediatr Drug* 2001; 3(4): 293-319.
 155. Whelton PK, Carey RM, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the

- American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol* 2017;S0735-1097:41519-1
156. Kimura Y et al. Treatment of chronic pain in pediatric rheumatic disease. *Nat Clin Pract Rheumatol* 2007; 3:210-218
 157. Sidhu S et al. Estrogen-based therapy for acute dysfunctional uterine bleeding. *CPJ/RPC* 2006; 139(3): 60-61
 158. Sidhu J, Job S, Singh S, et al, "The Pharmacokinetic and Pharmacodynamic Consequences of the Co-administration of Lamotrigine and a Combined Oral Contraceptive in Healthy Female Subjects," *Br J Clin Pharmacol*, 2006, 61(2):191-9.
 159. Kerwin et al. A dose-ranging study of epinephrine hydrofluoroalkane metered-dose inhaler (Primatene Mist) in subjects with mild to moderate persistent asthma. *J Aerosol Med Pulm Drug Deliv* 2020;33..
 160. Canadian Attention Deficit Hyperactivity Disorder Resource Alliance: Canadian ADHD Practice Guidelines, 4.1 Edition, Toronto ON; CADDRA, 2020. www.caddra.ca
 161. Nick JA. Non tuberculous mycobacteria in cystic fibrosis. *Seminars in Respiratory and Critical Care Medicine* 2003; 24(6): 693-702.
 162. Riikonen R. Infantile spasms: therapy and outcome. *J Child Neurol* 2004;19:401–404.
 163. Gore L et al. Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. *Pediatr Blood Cancer* 2009; 52:242-7.
 164. Williams DG et al. Pharmacogenetics of codeine metabolism in an urban population of children and its implications for analgesic reliability. *Br J Anaesth* 2002; 89: 839-45.
 165. Curry JI et al. Erythromycin as a prokinetic agent in infants and children. *Aliment Pharmacol Ther* 2001; 15(5); 595-603.
 166. Long R, Avendano M, Kunimoto D. Canadian Tuberculosis Standards 7th Edition. 2013. Chapter 8: Drug-Resistant Tuberculosis
 167. Al-Dabbagh M, Lapphra K, McGloin R, et al. Drug-resistant tuberculosis: pediatric guidelines. *Pediatr Infect Dis J* 2011;30:501-5.
 168. Mier RJ et al. Treatment of Sialorrhea with Glycopyrrolate- A Double-blind Dose-Ranging Study. *Arch Pediatr Adolesc Med.* 2000; 154(12): 1214-1218
 169. Elbe D, Carandang CG. Focus on Ziprasidone: A Review of its use in Child and Adolescent Psychiatry. *Journal of the Canadian Academy of Child and Adolescent Psychiatry* 2008; 17: 220-9
 170. Public Health Agency of Canada. Canadian Guidelines on Sexually Transmitted Infections [Internet]. 2010 [cited 2015 May 11]. Available from: <http://www.phac-aspc.gc.ca/std-mts/sti-its/cgsti-ldcits/section-5-10-eng.php>
 171. BCCH C. difficile order set. Approved 2016.
 172. Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant *Staphylococcus aureus* infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. *Am J Health Syst Pharm.* 2020;77(11):835–63
 173. Giachetto G et al. Ampicillin and penicillin concentration in serum and pleural fluid of hospitalized children with community-acquired pneumonia. *Pediatr Infect Dis J* 2004; 23: 625-629
 174. Aaronson PMA et al. Evaluation of intramuscular fosphenytoin vs intravenous phenytoin loading dose in the ED. *Am J Emerg Med* 2010; 29: 983-988
 175. Mueller EW et al. Fosphenytoin: Current place in therapy. *J Pediatr Pharmacol Ther* 2004. 9 (4):265-273
 176. Emil S, Nguyen T, Sills J et al. Meconium Obstruction in Extremely Low Birth Weight Neonates: Guidelines for Diagnosis and Management. *J Pediatr Surg* 39;5:731-37
 177. Cohen-Wolkowicz M, Watt KM, Zhou C et al. Developmental pharmacokinetics of piperacillin and tazobactam using plasma and dried blood spots from infants. *Antimicrobial Agents and Chemother* 2014;58:2856-65
 178. Cies JJ et al. Pharmacokinetics of piperacillin/tazobactam in critically ill young children. *Pediatr Infect Dis J* 2014;33:168–173
 179. Shann F. Drug Doses. Royal Children's Hospital, Melbourne Australia. 15th Edition. 2010

180. Driscoll TA, Yu LC, Frangoul H, et al. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults. *Antimicrob Agents Chemother* 2011; 55(12): 5770-5779
181. Choi SH, Lee SY, Hwang JY, et al. Importance of voriconazole therapeutic drug monitoring in pediatric cancer patients with invasive aspergillosis. *Pediatr Blood Cancer* 2013;60:82-87.
182. Monitto et al. The optimal dose of prophylactic intravenous naloxone in ameliorating opioid-induced side effects in children receiving intravenous patient-controlled analgesia morphine for moderate to severe pain: a dose finding study. *Anesth Analg*. 2011. 113(4):834-42.
183. Escudero C, Carr R, Sanatani S. Overview of antiarrhythmic drug therapy for supraventricular tachycardia. *Prog Pediatr Cardiol* 2013;35:55-63.
184. Perez V, Saenz D, Madriz J et al. A double-blind study of the efficacy and safety of multiple daily doses of amikacin versus one daily dose for children with perforated appendicitis in Costa Rica. *Int J Infect Dis* 2011;15:e569-75
185. Greenaway M, Elbe D. Focus on Aripiprazole: A Review of its use in Child and Adolescent Psychiatry. *Journal Can Acad Child Adolesc Psychiatry* 2009; 18: 250-60.
186. Correll CU, Manu P, Olshanskiy V et al. Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents. *J Am Med Assoc* 2009; 302: 176-573.
187. Pringsheim T, Panagiotopoulos C, Davidson J et al. Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth. *Pediatr Child Health* 2011; 16: 581-9.
188. Malik BA, Xie YY, Wine E et al. Diagnosis and pharmacological management of small intestinal bacterial overgrowth in children with intestinal failure. *Can J Gastroenterol* 2011;25:41-5
189. Loughheed MD, Lemiere C, Ducharme FM, et al; Canadian Thoracic Society Asthma Clinical Assembly. Canadian Thoracic Society 2012 guideline update: Diagnosis and management of asthma in preschoolers, children and adults. *Can Respir J* 2012;19(2):127-164.
190. Akhavan, A., & Bershada, S. Topical acne drugs: review of clinical properties, systemic exposure, and safety. *American Journal of Clinical Dermatology* 2003; 4(7), 473-492.
191. Evaluation and treatment of constipation in infants and children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. *J Pediatr Gastroenterol Nutr* 2006;43: e1-13
192. Munoz R et al (eds). *Handbook of Pediatric Cardiovascular Pharmacotherapy*. Second edition. Springer: 2014.
193. Fourth Report on Diagnosis, Evaluation and Treatment of High blood pressure in Children and Adolescents. *Pediatrics* 2004; 114(2): 555-576.
194. Del Cuvillo A et al. Use of antihistamines in pediatrics. *Investig Allergol Clin Immunol* 2007; 17 Suppl 2: 28-40.
195. Banerji A et al. Diphenhydramine versus nonsedating antihistamines for acute allergic reactions: a literature review. *Allergy Asthma Proc*. 2007; 28(4):418–426.
196. Wong-Sefdan I et al.). Implementing inpatient, evidence-based, antihistamine-transfusion premedication guidelines at a single academic US hospital. *The Journal of community and supportive oncology*, (2014 12(2), 56.
197. Alvesco © (ciclesonide inhalation aerosol). *Drug Product Monograph*. Nycomed Canada Inc. 2009.
198. Yang CL et al. 2021 Canadian Thoracic Society Guideline – A focused update on the management of very mild and mild asthma. *Can J Respir Crit Care Sleep Med*. 2021; 5(4): 205-245
199. Khongphattbanayothin A et al. Effects of cisapride on QT interval in children. *J Pediatr* 1998;133:51–56.
200. Shulman RJ et al. An updated medical position statement of the North American Society for Pediatric Gastroenterology and Nutrition. *J Pediatr Gastroenterol Nutr* 2000; 31: 232-233. cisapride
201. World Health Organization. *Guidelines for the Treatment of Malaria*. 2nd Edition. Geneva: World Health Organization; 2010
202. Thee S, Seddon JA, Donald PR et al. Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: Evidence for implementation of

- revised World Health Organization recommendations. *Antimicrob Agents Chemother* 2011;55:5560-7
203. BC Centre for Disease Control. Tuberculosis Control Manual. Section 5.0 Treatment of active TB disease. October 2019. Accessed Apr 27, 2022 <http://www.bccdc.ca/health-professionals/clinical-resources/communicable-disease-control-manual/tuberculosis>
 204. Taguchi N, Nishikawa T, Inomata S et al. Hemodynamic effects of intravenous ephedrine in infants and children anesthetized with halothane and nitrous oxide. *Anesth Analg* 1996;82:568-73
 205. See below
 205. Ly TT, Maahs DM, Rewers A et al. ISPAD Clinical Practice Consensus Guidelines 2014: Assessment and management of hypoglycemia in children and adolescents with diabetes. *Pediatric Diabetes* 2014;15(Suppl 20):180-92.
 206. Shannon M, Albers G, Burkart K et al. Safety and efficacy of flumazenil in the reversal of benzodiazepine-induced conscious sedation. The flumazenil Pediatric Study Group. *J Pediatr* 1997;131:582-6.
 207. Gharib H et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Growth Hormone Use in Adults and Children—2003 Update. *Endocr Pract* 2003; 9:64-76
 208. Wherrett et al. Canadian Diabetes Association. 2018 Clinical Practice Guidelines: Type 1 Diabetes in Children and Adolescents. *Can J Diabetes* 2018;42:S234–S246
 209. Kapoor RR, Flanagan SE, James C et al. Hyperinsulinaemic hypoglycemia. *Arch Dis Child* 2009;94:450-7
 210. Brendstrup L, Hjelt K, Petersen KE et al. Nitrofurantoin versus trimethoprim prophylaxis in recurrent urinary tract infections in children. *Acta Paediatr Scand* 1990;79:1225-34.
 211. Liu C, Bayer A, Cosgrove SE et al. Clinical Practice Guidelines by the Infectious Disease Society of America for the treatment of methicillin-resistant *Staphylococcus aureus* infections in adults and children: Executive summary. *Clin Infect Dis* 2011; 52:285-92
 212. Zeitlin L, Rauch F, Plotkin H et al. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, II, and IV. *Pediatrics* 2003;111:1030-6.
 213. Ohata Y, Tomita Y, Nakayama Y et al. Optimal dosage regimen of meropenem for pediatric patients based on pharmacokinetic/pharmacodynamic considerations. *Drug Metab Pharmacokinet* 2011;26:523-31.
 214. Cohen-Wolkowicz M, Poindexter B, Bidegain M. Safety and effectiveness of meropenem in infants with suspected or complicated intra-abdominal infections. *Clin Infect Dis* 2012;55:1495-502.
 215. Zeitler P, Fu J, Tandon N et al. ISPAD Clinical Practice Consensus Guidelines 2014: Type 2 diabetes in the child and adolescent. *Pediatric Diabetes* 2014;15(Suppl 20):26-46.
 216. Panagiotopoulos C, Riddell MC, Sellers EAC. Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: Type 2 diabetes in children and adolescents. *Can J Diabetes* 2013;37:S163-7.
 217. Ribeiro Barros E, Saraiva GL, Palomo de Oliveira T et al. Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. *J Pediatr Endocr Met* 2012;25:485-91.
 218. Vuorimies I, Toiviainen-Salo S, Hero M et al. Zoledronic acid treatment in children with osteogenesis imperfecta. *Horm Res Paediatr* 2011;75:346-53.
 219. White NJ et al. The anesthetic effectiveness of lidocaine-adrenaline-tetracaine gel on finger laceration. *Pediatr Emerg Care* 2004; 20: 812-5
 220. Priestly C et al. Application of topical local anesthetic at triage reduces treatment time for children with lacerations: A randomized controlled trial. *Ann Emerg Med* 2003; 42: 34-40.
 221. Hsu DC. Topical anesthetics in children. In: UpToDate. Stack AM (ed) UpToDate. Waltham, MA. (accessed Jan 26, 2015)
 222. Little C et al. The use of topical anesthesia during repair of minor lacerations I departments of emergency medicine: A literature review. *Int Emerg Nursing* 2009; 17: 99-107
 223. The RIVUR trial investigators. Antimicrobial prophylaxis for children with vesicoureteral reflux. *N Engl J Med* 2014; 370:2367-76

224. Craig JC, Simpson JM, Williams GJ et al. Antibiotic prophylaxis and recurrent urinary tract infection in children. *N Engl J Med* 2009;361:1848-59
225. Ohata Y. Intermittent oral trimethoprim/sulfamethoxazole on two non-consecutive days per week is effective as *Pneumocystis jirovecii* pneumonia prophylaxis in pediatric patients receiving chemotherapy or hematopoietic stem cell transplantation. *Pediatr Blood Cancer* 2009;52:142-4.
226. Sung L, Manji A, Beyene J et al. Fluoroquinolones in children with fever and neutropenia. *Pediatr Infect Dis J* 2012;31:431-5
227. Bradley JS, Byinton CL, Shah SS, et al. The Management of Community Acquired Pneumonia in Infants and Children Older than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Disease Society and the Infectious Disease Society of America. *Clin Infect Dis*, 2011; 53(7): e25-76.
228. Cloxacillin for injection. Prescribing Information. SteriMax Inc. Oakville ON. Feb 14, 2019. Accessed Apr 26, 2022. https://pdf.hres.ca/dpd_pm/00049752.PDF
229. Le Saux N. Guidelines for the management of suspected and confirmed bacterial meningitis in Canadian children older than 2 months of age. Canadian Pediatric Society. Oct 19, 2020. Accessed Apr 26, 2022 <https://cps.ca/en/documents/position/management-of-bacterial-meningitis>
230. Solomkin JS, Mazuski JE, Bradley JS, et al, "Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America," *Clin Infect Dis*, 2010, 50(2):133-64.
231. Pringsheim T, Panagiotopoulos C, Davidson J et al. Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth. *Pediatr Child Health* 2011; 16: 581-9.
232. Ronaldson KJ, Fitzgerald PB, Taylor AJ et al. A new monitoring protocol for clozapine induced myocarditis based on an analysis of 75 cases and 94 controls. *Aust N Z J Psychiatry* 2011; 45: 458-65.
233. American Academy of Child and Adolescent Psychiatry. Practice Parameter for the Assessment and Treatment of Children and Adolescents with Obsessive-Compulsive Disorder. *J Am Acad Child Adolesc Psychiatry* 2012; 51: 98–113.
234. Warren AE, Hamilton RM, Belanger SA et al. Cardiac risk assessment before the use of stimulant medications in children and youth: A joint position statement by the Canadian Paediatric Society, the Canadian Cardiovascular Society, and the Canadian Academy of Child and Adolescent Psychiatry. *Can J Cardiol* 2009; 25: 625-30.
235. Greil W, Bauer J, Breit J et al. Single daily dose schedule in lithium long-term treatment: effects on pharmacokinetics and on renal and cardiac functions. *Pharmacopsychiat* 1985; 18: 106-7.
236. Timmer RT, Sands JM. Lithium intoxication. *J Am Soc Nephrol*. 1999; 10: 666-74.
237. Bruni O, Alonso-Alconada D, Besag F et al. Current role of melatonin in pediatric neurology: Clinical recommendations. *Eur J Pediatr Neurol* 2015; 19: 122-33.
238. Emslie GJ, Wagner KD, Kutcher S. Paroxetine treatment in children and adolescents with major depressive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. *J Am Acad Child Adolesc Psychiatry*. 2006; 45: 709-19
239. IMO VANE (zopiclone) - New Dosage Recommendations to Minimize the Risk of Next-Day Impairment - For Health Professionals <http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2014/42253a-eng.php>
240. European medicines Agency. PRAC recommends restricting use of domperidone. European Medicines Agency 2012: EMA/129231/2014
241. Health Canada. MedEffect Advisory. January 15, 2015. Domperidone – Association with Serious Abnormal Heart Rhythms and Sudden Death (Cardiac arrest) – For Health Professionals <http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2015/43423a-eng.php>
242. Escudero C et al. Medical Management of Pediatric arrhythmias. *Curr Treat Options Cardiovasc Med* 2012; 14: 455-72
243. Escudero C et al. Overview of antiarrhythmic drug therapy for supraventricular tachycardia in children. *Prog in pediatr Cardiol* 2013; 35: 55-63.
244. Workowski KA, Bolan GA. Centers for Disease Control and Prevention (CDC). Sexually Transmitted Diseases Treatment Guidelines. *MMWR Morb Mortal Wkly Rep* 2015; 64 (RR 3): 1-137

245. Ortiz-Alvarez, O and Canadian Pediatric Society. Acute Management of croup in the emergency department. *Pediatr Child Health* 2017. 22(3):166-169
246. Canadian Dental Association Position on Use of Fluorides in Caries Prevention. Approved February 2021. http://www.cda-adc.ca/en/about/position_statements/fluoride/
247. Twycross R et al. Palliative Care Formulary- Canadian Edition. palliatedrugs.com Ltd. 2007, page 466
248. Parr JR et al. Drooling Reduction Intervention randomized trial (DRI): Comparing the Efficacy and Acceptability of Hyoscine Patches and Glycopyrronium Liquid on Drooling in Children With Neurodisability. *Arch Dis Child* 2018; 103:371-376
249. BC Guidelines.ca. Guidelines & Protocols Advisory Committee. Iron Deficiency – Diagnosis and Management. 2019
250. AAP 2010 Diagnosis and Prevention of iron deficiency anemia in infants and young children (0-3 yrs of age). *Pediatrics* 2010; 126(5): 2010-2576
251. Domelloff M et al. Iron requirements of infants and toddlers. *JPGN* 2014; 58(1): 119-129.
252. Cray SE et al. Intravenous Iron Sucrose for Children with Iron Deficiency Failing to Respond to Oral Iron Therapy. *Pediatr Blood Cancer* 2011; 56:615-619
253. Kaplinsky C et al. Magnesium Homeostasis and hypomagnesemia in children with malignancy. *Pediatr Blood Cancer* 2013;60:734-40
254. Peltola H et al. Acute osteomyelitis in children. *N Engl J Med* 2014; 370: 352-60
255. American Academy of Pediatrics, Committee on Infectious Diseases. The use of systemic and topical fluoroquinolones. *Pediatrics* 2011;128(4):e1034-45.
256. Lehrnbecher T, Phillips R, Alexander S, et al. Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. *J Clin Oncol* 2012;30:4427-38.
257. Vanek VW, Borum P, Buchman A et al. ASPEN Position Paper: Recommendations for changes in commercially available parenteral multivitamin and multi-trace element products. *Nutr Clin Pract*. Aug 2012; 27(4): 440-491.
258. Popovich D, McAlhany A, Adewumi AO, Barnes MM. Scurvy: Forgotten but definitely not gone. *J Pediatr Health Care*. (2009);23:405-415.
259. Nelson's Essentials of Pediatrics 7th edition (online version) Vitamins and Minerals Marc dante and Kleigman 2015
260. Sathe M et al. Update in pediatrics: focus on fat-soluble vitamins. *Nutrition in Clinical Practice* 2010. 25 (4): 340-346.
261. Flynn JT et al. Management of hypertension in the young: role of antihypertensive medications. *J Cardiovasc Pharmacol* 2011;58 (2): 111-120.
262. Le Saux N, Robinson JL; Canadian Paediatric Society Infectious Diseases and Immunization Committee. Management of acute otitis media in children six months of age and older. *Paediatr Child Health* 2016;21:39-44
263. Malani AN. Failure of caspofungin for treatment of *Candida glabrata* candiduria: case report and review of the literature. *Infect Dis Clin Pract* 2010;18:271.
264. Sobel JD, Bradshaw SK, Lipka CJ, Kartsonis NA. Caspofungin in the treatment of symptomatic candiduria. *Clin Infect Dis* 2007;44:e46-9.
265. Cornely OA et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. *N Engl J Med* 2007; 356: 348-59
266. Patterson TF, Thompson GR, Denning DW et al. Practice Guidelines for the diagnosis and management of aspergillosis: 2016 Update by the Infectious Diseases Society of America. *Clin Inf Dis* 2016;63:e1-60
267. Freifeld AG et al. Clinical Practice Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America. *Clin Inf Dis* 2011; 51: e56-e93.
268. Krishna G, Moton A, Ma L, Medlock MM, McLeod J. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. *Antimicrob Agents Chemother* 2009;53(3):958-966.
269. Ullman AJ et al. Posaconazole or fluconazole in severe graft-versus-host disease. *N Engl J Med* 2007; 356: 335-47.

270. Allen UD; Canadian Paediatric Society. Antifungal agents for the treatment of systemic fungal infections in children. *Paediatr Child Health* 2010;15(9):603-8.
271. Zalmanovici Trestioreanu A, Yaphe J. Intranasal steroids for acute sinusitis. *Cochrane Database of Systematic Reviews* 2013, Issue 12. Art. No.: CD005149. DOI: 10.1002/14651858.CD005149.pub4
272. Ortiz-Alvarez O, A Mikrogianakis; Canadian Paediatric Society, Acute Care Committee. Managing the paediatric patient with an acute asthma exacerbation. *Paediatr Child Health* 2012;17(5):251-256.
273. Griffiths B, Ducharme FM. Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. *Cochrane Database of Systematic Reviews* 2013, Issue 8. Art. No.: CD000060. DOI: 10.1002/14651858.CD000060.pub2
274. Del Cuvillo O, et al. Use of antihistamines in pediatrics. *J Investig Allergol Clin Immunol* 2007. 17 Suppl 2: 28-40
275. Chauhan BF, Ben Salah R, Ducharme FM. Addition of anti-leukotriene agents to inhaled corticosteroids in children with persistent asthma. *Cochrane Database of Systematic Reviews* 2013, Issue 10. Art. No.: CD009585. DOI: 10.1002/14651858.CD009585.pub2.
276. Vézina K, Chauhan BF, Ducharme FM. Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. *Cochrane Database of Systematic Reviews* 2014, Issue 7. Art. No.: CD010283. DOI: 10.1002/14651858.CD010283.pub2.
277. McDonald N, Bara A, McKean MC. Anticholinergic therapy for chronic asthma in children over two years of age. *Cochrane Database of Systematic Reviews* 2003, Issue 3. Art. No.: CD003535. DOI: 10.1002/14651858.CD003535.
278. Koninkx M et al. Management of Status Asthmaticus in Children. *Pediatric Respiratory Reviews* 2013; 14: 78-85
279. Methylprednisolone High Dose (Pulse) Therapy Protocol. Approved by BCCH PTN Dec 13, 2016.
280. *Kidney International Supplements* (2012) 2;292-298 Chapter 2: use of iron to treat anemia in CKD The 2012 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Anemia in Chronic Kidney Disease
281. Jordan CP et al. Universal ECG changes in pediatric patients undergoing procainamide challenge. *PACE* 2014; 37: 1106-10.
282. Plambeck MZ et al. Dexmedetomidine in the pediatrics population: a review. *Minerva Anesthesiol* 2015; 81:320-32.
283. Li BL et al. Intranasal dexmedetomidine following failed chloral hydrate sedation in children. *Anaesthesia* 2014; 69: 240-4.
284. Ibrahim M. A prospective, randomized, double blinded comparison of intranasal dexmedetomidine vs intranasal ketamine in combination with intravenous midazolam for procedural sedation in school aged children undergoing MRI. *Anesth Essays Res* 2014; 8: 179-86.
285. Hitt JM et al. An evaluation of intranasal sufentanil and dexmedetomidine for pediatric dental sedation. *Pharmaceutics* 2014; 6: 175-84.
286. Wang SS et al. The sedative effects and the attenuation of cardiovascular and arousal responses during anesthesia induction and intubation in pediatric patients: a randomized comparison between two different doses of preoperative intranasal dexmedetomidine. *Paediatr Anaesth* 2014; 24: 275-81.
287. Rivkees SA. Pediatric Graves' disease: management in the post-propylthiouracil era. *Int J Pediatr Endocrinol*. 2014;2014(1):10. Epub 2014 Jun 16
288. American Academy of Pediatrics. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. *Pediatrics* 2014;134:e620-38.
289. Stabler S. Vitamin B 12 Deficiency. *NEJM* Jan 2013, Vol 368:149-160
290. Guidelines and Protocols Advisory Committee, British Columbia Medical Association, Medical Services Commission (MSC). Cobalamin (vitamin B12) deficiency - investigation and

- management. (Revised May 1, 2013) www2.gov.bc.ca/assets/gov/health/practitioner-pro/bc-guidelines/cobalamin.pdf
291. Canadian Paediatric Society Position Statement: Vegetarian Diets in Children and Adolescents. *Paediatr Child Health* 2010; 15(5): 303-314 (Reaffirmed Feb 28, 2018)
 292. Lauer B et al. Vitamins. *Pediatrics in Review*. Aug 2012; 33(8): 339-352.
 293. Firazyr® (icatibant) [Health Canada Product Monograph]. Shire Orphan Therapies, LLC. Lexington, MA. Last revision: November 19, 2015.
 294. Li JS et al. Dosing of Clopidogrel for Platelet Inhibition in Infants and young children primary results of the platelet inhibition in Children on Clopidogrel (PICOLO) *Circulation* 2008; 117:553-559
 295. Litalien C, et al. Pharmacokinetics of proton pump inhibitors in children. *Clin Pharmacokinet* 2005; 44(5):441-466
 296. Tolia V, et al. Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children. *JPGN* 2002; 35:S308-312
 297. Vandenasplas Y et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). *J Pediatr Gastroenterol Nutr*. 2009 Oct;49(4):498-547.
 298. Long S, Pickering LK, Prober CG. Principles and Practice of Pediatric Infectious Diseases. Long, Pickering and Prober, 4th ed. Saunders Elsevier, 2012.
 299. Willoughby JL, Bowen CN. Zinc Deficiency and Toxicity in Pediatric Practice. *Curr Opin Pediatr*. 2014 Oct;26(5):579-84
 300. Appropriate Dosing for Parenteral Nutrition: ASPEN Recommendations. Nov 17, 2020. (https://www.nutritioncare.org/uploadedFiles/Documents/Guidelines_and_Clinical_Resources/PN%20Dosing%201-Sheet-Nov%202020-FINAL.pdf)
 301. ESPGHAN. Iron, minerals, trace elements. *Journal of Pediatric Gastroenterology and Nutrition*. 2006; 41:S39-S46
 302. Lowry CM, Marty FM, Vargas SO et al. Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study. *Transpl Infect Dis* 2007; 9: 121-125
 303. Saiman L et al. Azithromycin in patients with cystic fibrosis chronically infected with *Pseudomonas aeruginosa*: a randomized controlled trial. *JAMA* 2003;290:1749-56.
 304. Feldman WE, Moffitt S, and Sprow N, Clinical and Pharmacokinetic Evaluation of Parenteral Cefoxitin in Infants and Children, *Antimicrob Agents Chemother*, 1980, 17(4):669-74
 305. Spino M, Chai RP, Isles AF et al. Cloxacillin absorption and disposition in cystic fibrosis. *J Pediatr* 1984;105(5):829-35
 306. Young DC, Zobell JT, Waters CD et al. Optimization of Anti-Pseudomonal Antibiotics for Cystic Fibrosis Pulmonary Exacerbations: IV. Colistimethate Sodium. *Pediatr Pulmonol* 2013; 48:1-7.
 307. Rosenfeld et al. Inhaled Hypertonic Saline in Infants and Children Younger Than 6 Years With Cystic Fibrosis. *JAMA* 2012; 307(21):2269-77.
 308. Shneider BL, Magee JC, Bezerra JA, Haber B et al. Efficacy of fat-soluble vitamin supplementation in infants with biliary atresia. *Pediatrics*. 2012; 130(3): e607-e614.
 309. Lauer B and Spector N. Vitamins. *Pediatrics in Review*, Aug 2012; 33(8):339-352
 310. Tangpricha V et al. An Update on the Screening, Diagnosis, Management, and Treatment of Vitamin D Deficiency in Individuals with Cystic Fibrosis: Evidence-Based Recommendations from the Cystic Fibrosis Foundation. *J Clin Endocrinol Metab* 2012;97(4):1-12.
 311. Willot S et al. Effect of Ursodeoxycholic Acid on Liver Function in Children After Successful Surgery for Biliary Atresia. *Pediatrics* 2008;122:e1236-41.
 312. El-Shabrawi MHF, et al. Medical Management of Chronic Liver Disease in Children (Part II): focus on the complications of CLD, and CLD that require special considerations. *Pediatr Drugs* 2011; 13(6): 371-83.
 313. Eaton JE et al. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. *Am J Gastroenterol* 2011; 106(9): 1638-45.

314. Prophylaxis and treatment recommendations for sinusoidal obstruction syndrome in adult and pediatric patients undergoing hematopoietic stem cell transplant: a review of the literature. *J Oncol Pharm Pract* 2011.
315. Keeney GE et al. Dexamethasone for acute asthma exacerbations in children: a meta-analysis. *Pediatrics* 2014; 133: 493-499.
316. Product Information: ORENCIA(R) intravenous subcutaneous injection, abatacept intravenous subcutaneous injection. Bristol-Myers Squibb (per manufacturer), Princeton, NJ, 2011.
317. Ringold S, Weiss PF, Beukelman T, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. *Arthritis Care Res (Hoboken)* 2013; 65:1551.
318. Ruperto N et al. Long-Term Safety and Efficacy of Abatacept in Children with Juvenile Idiopathic Arthritis. *Arthritis Rheum* 2010;62:1792–1802.
319. Ruperto N et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. *Lancet* 2008; 372: 383-91.
320. Kingsbury DJ, Bader-Meunier B, Patel G, et al. Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years. *Clin Rheumatol.* 2014;33(10):1433–1441.
321. Ruemmele et al. Consensus Guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. *J Crohn's and Colitis* 2014;8:1179-1207
322. Ringold S, Weiss PF, Beukelman T, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. *Arthritis Care Res (Hoboken)* 2013; 65:1551.
323. Lovell DJ et al. Adalimumab with or without methotrexate for juvenile rheumatoid arthritis. *N Engl J Med* 2008;359:810-20
324. Kingsburey DJ, Bader-Meunier B, Patel G, Arora V, Kalabic J et al. Safety, effectiveness and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years. *Clin Rheumatol* 2014;33:1433-41.
325. Ilowite N et al. Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. *Clin Rheumatol* 2009; 28:129–137.
326. Dewitt EM, Kimura Y, Beukelman T, Nigrovic PA, Onel K et al. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. *Arthritis Care Res (Hoboken)* 2012;64:1001-10.
327. Wallace CA, Ringold S, Bohnsack J, Spalding SJ, Brunner HI et al. Extension study of participants from the trial of early aggressive therapy in juvenile idiopathic arthritis. *J Rheumatol* 2014;41:2459-65
328. Horneff G. Safety of biologic therapies for the treatment of juvenile idiopathic arthritis. *Expert Opin Drug Safety* 2015;14:1111-26.
329. Kliegman RM and St. Geme J, eds. *Nelson Textbook of Pediatrics*. 21st ed. Philadelphia, PA: Saunders Elsevier; 2020..
330. Product Information: ACTEMRA tocilizumab solution for injection. Hoffmann-La Roche Limited. Mississauga, Ontario 2015.
331. Brunner HI, Ruperto N, Zuber Z, Keane C, Harari O. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. *Ann Rheum Dis* 2015;74:1110-7.
332. Yokota S, Imagawa T, Mori M, Miyamae T, Takei S et al. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan. *J Rheumatol* 2014;41:759-67.
333. Hawkins MJ, Dick AD, Lee RJW, Ramanan AV, Guly CM et al. Managing juvenile idiopathic arthritis-associated uveitis. *Survey Ophthalmology* 2016;61:197-210.
334. Cormier, J, Chu, C. Safety and efficacy of levetiracetam for the treatment of partial onset seizures in children from one month of age. *Neuropsychiatric Disease and Treatment* 2013; 9: 295-306.

335. Vaisleib, I, Neft, R. Rapid Dosage Titration of Levetiracetam in Children. *Pharmacotherapy* 2008; 28 (3): 393-396 (For more rapid titration – cut out day increment)
336. Brophy, G et al. Guidelines for the Evaluation and Management of Status Epilepticus. *Neurocritical Care* 2012; 17(1): 3-23
337. Guerrini, R., "Valproate as a Mainstay of Therapy for Pediatric Epilepsy." *Pediatr Drugs*. 2006; 8(2): 113-129
338. Graves NM and Kriel RL, "Rectal Administration of Antiepileptic Drugs in Children," *Pediatr Neurol*, 1987, 3(6):321-6
339. BCCH Pediatric Critical Care Program. Enteral and Parenteral nutrition support guidelines. Supplementation guidelines page 55. Last review date Apr 18, 2009.
340. Misra M et al. Vitamin D Deficiency in Children and Its Management: Review of Current Knowledge and Recommendations. *Pediatrics* 2008, 122(2): 398-417
341. Canadian Pediatric Society. Bronchiolitis: Recommendations for diagnosis, monitoring and management of children one to 24 months of age. Position Statement. Updated Jan 31, 2018
342. Ralston SL, Lieberthal AS, Meissner HC, Alverson BK, Baley JE, Gadomski AM, et al. Clinical Practice Guideline: The Diagnosis, Management, and Prevention of Bronchiolitis. *PEDIATRICS*. 2014 Nov 1;134(5):e1474–e1502.
343. Zhang L, Mendoza-Sassi RA, Wainwright C, Klassen TP. Nebulised hypertonic saline solution for acute bronchiolitis in infants. In: The Cochrane Collaboration, editor. *Cochrane Database of Systematic Reviews* [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2013 [cited 2015 Mar 10]. Available from: <http://doi.wiley.com/10.1002/14651858.CD006458.pub3>
344. Chen Y-J, Lee W-L, Wang C-M, Chou H-H. Nebulized Hypertonic Saline Treatment Reduces Both Rate and Duration of Hospitalization for Acute Bronchiolitis in Infants: An Updated Meta-analysis. *Pediatr Neonatol*. 2014 Dec;55(6):431–8.
345. Maguire C, Cantrill H, Hind D, Bradburn M, Everard ML. Hypertonic saline (HS) for acute bronchiolitis: Systematic review and meta-analysis. *BMC Pulm Med*. 2015;15:148.
346. Zhang L, Mendoza-Sassi RA, Klassen TP, Wainwright C. Nebulized Hypertonic Saline for Acute Bronchiolitis: A Systematic Review. *Pediatrics*. 2015 Oct;136(4):687–701.
347. Lumba-Brown A, Harley J, Lucio S et al. Hypertonic saline as a therapy for pediatric concussive pain. *Pediatr Emerg Care* 2014;30:139-45.
348. Mortazaci MM, Romeo AK, Deep A et al. Hypertonic saline for treating raised intracranial pressure: literature review and meta-analysis. *J Neurosurg* 012;116:210- 21.
349. Quick Review Summary. Guideline for prevent of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients. Pediatric Oncology Group of Ontario; Toronto, Jan 21, 2021 <http://www.pogo.ca/healthcare/practiceguidelines>
350. British Columbia Cancer Agency Policy Number III-20.Prevention and management of extravasation of chemotherapy. Revised Jan 2016.
351. Brier ME, Gaylor SK, McGovren JP, et al, "Pharmacokinetics of Dexrazoxane in Subjects With Impaired Kidney Function," *J Clin Pharmacol*, 2011, 51(5):731-8.
352. Lipshultz SE, Scully RE, Lipsitz SR, et al, "Assessment of Dexrazoxane as a Cardioprotectant in Doxorubicin-Treated Children With High-Risk Acute Lymphoblastic Leukaemia: Long-Term Follow-Up of a Prospective, Randomised, Multicentre Trial," *Lancet Oncol*, 2010, 11(10):950-61
353. Daly K, Farrington E. Hypokalemia and hyperkalemia in infants and children: pathophysiology and treatment. *J Ped Health Care* 2013. 27(6): 486-96.
354. Masilamani K, van der Voort J. The management of acute hyperkalaemia in neonates and children. *Arch Dis Child* 2012; 97: 376-380
355. Allen UD, Robinson JL; Canadian Paediatric Society Infectious Diseases and Immunization Committee. Prevention and management of neonatal herpes simplex virus infections. *Paediatr Child Health* 2014;19(4):201-6.
356. James SH, Whitley RJ. Treatment of Herpes simplex virus infections in pediatric patients: current status and future needs. *Clin Pharmacol Ther* 2010; 88(5):720-24
357. Feigin RD, Cherry J, Demmler-Harrison GJ, Kaplan SL. *Textbook of pediatric infectious diseases*. 7th ed. Philadelphia: Saunders Elsevier; 2014.
358. BCCH hematology/oncology bone marrow transplant supportive care guidelines 2012.,
359. Bomgaars L et al. Valacyclovir and acyclovir pharmacokinetics in immunocompromised children. *Pediatr Blood Cancer* 2008; 51 (4): 504-8.

360. Kimberlin DW et al. Pharmokinetics and safety of extemporaneously compounded valacyclovir oral suspension in pediatric patients from 1 month through 11 years of age. *Clin Infect Dis* 2010; 50(2): 221
361. Reiss WB et al. Acetazolamide in the treatment of seizures. *Ann Pharmacother*, 1996; 30(5): 514-9.
362. Giraud C et al. In vitro Characterization of Clobazam metabolism by Recombinant Cytochrome P450 Enzymes: Importance of CP2C19. *Drug Metab Dispos* 2004; 32(11): 1279-86.
363. Malu C et al. Efficacy of sublingual lorazepam vs intrarectal diazepam for prolonged convulsions in sub-Saharan Africa. *J Child Neurol* 2014; 29(7): 895-902.
364. Friedman JN. Canadian Pediatric Society. Emergency management of the paediatric patient with generalized convulsive status epilepticus. *Paediatr Child Health* 2011; 16(2): 91-7.
365. Albani F et al. Immediate (overnight) switching from carbamazepine to oxycarbazepine monotherapy is equivalent to a progressive switch. *Seizure* 2004; 13: 254-263.
366. Yeung S, Ensom M. Phenytoin and enteral feedings: Does Evidence support an interaction? *Ann Pharmacother* 2000; 34: 896-904.
367. Dellinger RP et al. Surviving sepsis campaign: International guidelines for the management of severe sepsis and septic shock: 22008. *Intensive Care Med* 2008; 34: 17-60
368. Menon K et al. A systematic review and meta-analysis on the effect of steroids in pediatric shock. *Pediatr Crit Care Med* 2013; 14: 474-80.
369. Shulman D et al. Adrenal insufficiency: Still a cause of morbidity and death in childhood. *Pediatrics* 2007; 119: e484-94.
370. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. *Clin Infect Dis* 2010;50:291-322.
371. Mutanen A, Pakarinen MP. Perianal crohn's disease in children and adolescents. *Eur J Pediatr Surg* 2022;30:395-400
372. Sato N et al. Treatment situation of male hypogonadotropic hypogonadism in pediatrics and proposal of testosterone and gonadotropin replacement therapy protocols. *Clin Pediatr Endocrinol* 2015; 24(2): 37-49.
373. Esposito C et al. Comparison of five different hormonal treatment protocols for children with cryptorchidism. *Scan J Urol Nephrol* 2003; 37: 247-9.
374. Bertelloni S et al. Hormonal treatment for unilateral inguinal testis: Comparison of four different treatments. *Horm Res* 2001; 55: 236-239.
375. BCCH Endocrine test protocols. April 19, 2016.
376. Mallick U et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. *N Engl J Med*. 2012 May 3;366(18):1674-85.
377. Francis GL et al. Management Guidelines for children with thyroid nodules and differentiated thyroid cancer. *Thyroid* 2015; 25 (7): 716-759.
378. Hochadel, M. [Editor]. *Mosby's Drug Reference for Health Professions 5th Edition*.
379. Azad R et al. Role of intravenous fluorescein angiography in early detection and regression of retinopathy of prematurity. *J Pediatr Ophthalmol Strabismus*. 2008; 45 (1): 36-9.
380. Lepore D et al. Atlas of fluorescein angiographic findings in eyes undergoing laser for retinopathy of prematurity. *Ophthalmology*. 2011; 118 (1): 168-75
381. Fattel-Valevski A et al. Outbreak of life-threatening thiamine deficiency in infants in Israel caused by defective soy based formula. *Pediatr* 2005; 115 (2): e233-237.
382. Smithline HA et al. Pharmacokinetics of high-dose oral thiamine hydrochloride in healthy subjects *BMC Clinical Pharmacology*. 2012; 12 (4).
383. Charron T et al. Intravenous phosphate in the intensive care unit: More aggressive repletion regimens for moderate and severe hypophosphatemia. *Intensive Care Med* 2003; 29: 1273-8.
384. Mack Dr et al. methotrexate in patients with Crohn's disease after 6-mercaptopurine. *J Pediatr* 1998. 132: 830-5.
385. Expert Panel Recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. *Ophthalmology* 2014; 121: 785-796.
386. Nono-Serna LF, Acosta-Reyes J, Veroniki AA et al. Antiemetics in children with acute gastroenteritis: A meta-analysis. *Pediatr* 2020;145:e20193260

387. Patel P, Robinson PD, Thackray J, Flank K, Holdsworth MT et al. Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: A focused update. *Pediatr Blood Cancer* 2017;64:e26542
388. Galardy PJ et al. Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: A Children's Oncology Group Report. *BMJ* 2013; 163: 365-372.
389. Friedrichsdorf SJ et al. The management of pain in children with life-limiting illnesses. *Pediatr Clin N Am* 2007; 54: 645-72.
390. Hershey AD et al. Effectiveness of amitriptyline in the prophylactic management of childhood headaches. *Headache* 2000; 40: 539-49.
391. Wasiewski WW. Preventative therapy in pediatric migraine. *J Child Neurol* 2001; 16: 71-8.
392. Bonfert M et al. Primary headache in children and adolescents: update on pharmacotherapy of migraine and tension-type headache. *Neuropediatrics* 2013; 44: 3-19.
393. McGlone R et al. A comparison of intramuscular ketamine with high dose intramuscular midazolam with and without intranasal flumazenil in children before suturing. *Emerg Med J* 2001; 18: 34-8.
394. Health Canada Information Update. Health Canada's review recommends codeine only be used in patients aged 12 and over. June 6, 2013. Accessed at: <http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/33915a-eng.php>
395. Health Canada Information Update. Health Canada recommends that children and youth not use cough and cold products that contain opioids. Feb 18, 2019. Accessed at <https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2019/69080a-eng.php>
396. Health Canada Information Update. New safety measures for prescription codeine and hydrocodone to further restrict use in children and adolescents. July 28, 2016. Accessed at <http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2016/59584a-eng.php>
397. FDA Drug Safety Communication. Safety review update of codeine use in children; new Boxed Warning and Contraindication on use after tonsillectomy and/or adenoidectomy. August 15, 2012. Accessed at: <http://www.fda.gov/downloads/Drugs/DrugSafety/UCM339116.pdf>
398. Sheehy KA et al. Subanesthetic ketamine infusions for the treatment of children and adolescents with chronic pain: a longitudinal study. *BMC Pediatr* 2015; 15: 198
399. Pestieau SR et al. Prolonged perioperative infusion of low-dose ketamine does not alter opioid use after pediatric scoliosis surgery. *Pediatr Anesthesia* 2014; 24: 582-90.
400. Holh CM et al. Methotrimeprazine for the management of end-of-life symptoms in infants and children. *J Palliative Care* 2013; 29: 178-95.
401. Topjian AA et al. Part 4: Pediatric basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. *Circulation* 2020; 142(suppl 2); S469-S523
402. Miller JL, Hagemann TM. Use of pure opioids antagonists for management of opioid-induced pruritis. *Am J Health Syst Pharm* 2011; 68(15): 1419-1425.
403. Maxwell LG et al. The effects of a small-dose naloxone infusion on opioid-induced side effects and analgesia in children and adolescents treated with intravenous patient-controlled analgesia: a double-blind, prospective, randomized, controlled study. *Anesth Anal* 2005; 100: 953-8.
404. Ganesh A et al. Pathophysiology and management of opioid-induced pruritus. *Drugs* 2007; 67(16): 2323-33.
405. Committee on Gynecologic Practice. The American College of Obstetrics and Gynecology. Management of acute abnormal uterine bleeding in nonpregnant reproductive-aged women. *Obstetrics and Gynecology* 2014; 121: 891-6.
406. Kasap B. Sirolimus in pediatric renal transplantation. *Pediatr Transplantation* 2011; 15: 673-85.
407. Pape L et al. mTOR inhibitors in pediatric kidney transplantation. *Pediatr Nephrol* 2014; 29:1119-1129
408. Ganschow R et al. Growing experience with mTOR inhibitors in pediatric solid organ transplantation. *Pediatr Transplantation* 2013;17:694-706
409. Kang HJ et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomized, double-blind, phase 3 trial. *Lancet Oncol* 2015; 16: 385-94.
410. Patel P, Robinson PD, Thackray J et al. Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: a focused update.

- Pediatr Blood Cancer. 2017 Oct;64(10):e26542
411. Friedrichsdorf SJ and Nugent AP. Management of Neuropathic Pain in Children with Cancer. *Current Opinion in Supportive and Palliative Care*. 2013 Jun 7(2): 131-8
412. Lipidrescue.org
413. SOGC Clinical Practice Guideline. Abnormal Uterine Bleeding Pre-Menopausal Women. *J Obstet Gynaecol Can* 2018;40(5):e391–e415
414. SOGC Clinical Practice Guidelines. Canadian Contraception Consensus, Chapter 8: Progestin-only Contraception. *J Obstet Gynaecol Can* 2016; 38 (3): 279-300
415. Meyers RS, Thackray J, Matson KL, et al. Key Potentially Inappropriate Drugs in Pediatrics: The KIDs List. *J Pediatr Pharmacol Ther*. 2020;25(3):175-191
416. Baena-Cagnani CE, Patel P. Efficacy and long-term safety of mometasone furoate nasal spray in children with perennial allergic rhinitis. *Curr Med Res Opin* 2010;26:2047-55.
417. Ortiz de la Rosa JS, Ladino LD, Rodriguez PJ, Rueda MC, Polania JP, Castaneda AC. Efficacy of lacosamide in children and adolescents with drug-resistant epilepsy and refractory status epilepticus: A systematic review. *Seizure*. 2018;56:34-40
418. Gross S et al. Efficacy and safety of lacosamide in infants and young children with refractory focal epilepsy. *Eur J Pediatr Neurol* 2014; 18: 55-59
419. Miskin C et al. Efficacy and tolerability of lacosamide in the treatment of children with refractory generalized epilepsy. *J Child Neurol* 2016; 31(7): 925-929
420. Sant' Anna AM, et al. Use of cyproheptadine in young children with difficulties and poor growth in a pediatric feeding program. ***J Pediatr Gastroenterol Nutr* 2014; 59: 674-678**
421. Chavhan GB et al. MR enterography in children: Principles, technique, and clinical applications. *Indian J Radiol Imaging*. 2013 Apr-Jun; 23(2): 173–178.
422. Tytgat GN. Hyoscine butylbromide: a review of its use in the treatment of abdominal cramping and pain. *Drugs*. 2007;67(9):1343-57
423. Tabbers MM et al. Evaluation and treatment of functional constipation in infants and children: evidence-based recommendations from ESPGHAN and NASPGHAN. *J Pediatr Gastroenterol Nutr*. 2014;58(2):258-274.
424. El-Shabrawi MH et al. Medical management of chronic liver diseases (CLD) in children (part II): focus on the complications of CLD, and CLD that require special considerations. *Paediatr Drugs*. 2011; 13(6):371-83.
425. Blei AT et al. Hepatic Encephalopathy. *Am J Gastroenterol*. 2001; 96(7):1968-76
426. Li ST, Grossman DC, and Cummings P, "Loperamide Therapy for Acute Diarrhea in Children: Systematic Review and Meta-analysis," *PLoS Med*, 2007, 4(3):e98.
427. Kaplan MA et al. A multicenter randomized controlled trial of liquid loperamide product versus placebo in the treatment of acute diarrhea in children. *Clin Pediatr (Phila)* 1999; 38: 579-591.
428. Sandhu BK, Tripp JH, Milla PJ, et al, "Loperamide in Severe Protracted Diarrhoea," *Arch Dis Child*, 1983, 58(1):39-43
429. Rufo PA et al. Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations. *J Pediatr Gastroenterol Nutr*. 2012;55(1):93-108
430. Health Canada. MedEffect Advisory. January 5, 2015. Metoclopramide – Abnormal involuntary movements (Extrapyramidal symptoms) in children. <http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2015/43167a-eng.php>
431. Koseoglu V, Kurekci AE, Sorici U. Comparison of the efficacy and side effects of ondansetron and metoclopramide-diphenhydramine administered to control nausea and vomiting in children treated with antineoplastic chemotherapy: A prospective randomized study. *Eur J Pediatr* 1998;157:806-10.
432. Vanderplas Y et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN). *J Pediatr Gastroenterol Nutr* 2009;49:498-547.
433. Blackmer AB et al. Constipation in the Pediatric Patient: An Overview and Pharmacologic Considerations. *J Pediatr Health Care*. 2010; 24: 385-399.
434. Tammara BK et al, "Randomized, Open-Label, Multicentre Pharmacokinetic Studies of Two Dose Levels of Pantoprazole Granules in Infants and Children Aged 1 Month Through <6 Years With Gastro-oesophageal Reflux Disease," *Clin Pharmacokinet*, 2011, 50(8):541-50.

435. Ward RM et al. A multicenter, randomized, open-label, pharmacokinetics and safety study of pantoprazole tablets in children and adolescents aged 6 through 16 years with GERD. *J Clin Pharmacol.* 2011;51(6):876-887.
436. Pettersen G et al. Population pharmacokinetics of intravenous pantoprazole in paediatric intensive care patients. *Br J Clin Pharmacol.* 2009;67(2):216-227
437. Tuggle DW et al. The safety and cost-effectiveness of polyethylene glycol electrolyte solution bowel preparation in infants and children. *J Pediatr Surg* 1987; 22(6): 513-5.
438. Sondheimer JM et al. Safety, efficacy and tolerance of intestinal lavage in pediatric patients undergoing diagnostic colonoscopy. *J Pediatr* 1991; 119(1):148-52
439. Turner et al. Pico-Salax versus polyethylene glycol for bowel cleanout before colonoscopy in children: a randomized controlled trial. *Endoscopy.* 2009;41(12):1038-45.
440. Carroll MW and Jacobson K. Gastroesophageal reflux disease in children and adolescents. *Pediatr Drugs* 2012; 14(2):79-89.
441. ASHP Therapeutic guidelines on stress ulcer prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. *Am J Health Syst Pharm.* 1999;56(4):347-379
442. Yildizdas D et al. Occurrence of ventilator-associated pneumonia in mechanically ventilated pediatric intensive care patients during stress ulcer prophylaxis with sucralfate, ranitidine, and omeprazole. *J Crit Care.* 2002 Dec;17(4):240-5.
443. Lopriore E et al. Ventilator-associated pneumonia and upper airway colonisation with Gram negative bacilli: the role of stress ulcer prophylaxis in children. *Intensive Care Med.* 2002 Jun;28(6):763-7
444. Hall B, Chesters J, Robinson, A. Infantile colic: A systematic review of medical and conventional therapies. *J Paediatrics Child Health* 2012; 48: 128-137.
445. Roberts EA, Schilsky ML. Diagnosis and treatment of Wilson Disease: An update. *Hepatology* 2008;47:2089-111
446. Quaas AM et al. Prevention and treatment of uterine bleeding in hematologic malignancy. *European Journal of Obstetrics and Gynecology and Reproductive Biology* 2007; 134: 3-8
447. Martin-Johnston MK et al. Therapeutic amenorrhea in patients at risk for thrombocytopenia. *Obstetrical and gynecological Survey* 2008: 63(6): 395-402.
448. James, AH et al. Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel. *Eur J Obstet Gynecol Reprod Biol* 2011; 158(2): 124-34.
449. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. *J Clin Oncol* 2017: 35 3240-3261.
450. Buchen S et al. Carboxypeptidase G₂ rescue in patients with methotrexate intoxication and renal failure. *Br J Cancer* 2005; 92: 480-487.
451. Bradley AM et al. Successful use of intrathecal carboxypeptidase G₂ for intrathecal methotrexate overdose: A clinical case study and review of the literature. *Clin Lymphoma* 2013; 13(2):166-70.
452. Voraxaze product monograph
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125327lbl.pdf
453. Tengborn L et al. Tranexamic acid—an old drug still going strong and making a revival. *Thrombosis research* 2015; 135: 231-242.
454. Khemani RG, Randolph A, Markovitz B. Corticosteroids for the prevention and treatment of post-extubation stridor in neonates, children and adults. *Cochrane Database Syst Rev* 2009;3:CD001000.
455. Sharar SR, Bratton SL, Carrougher GJ et al. Comparison of oral transmucosal fentanyl citrate and oral hydromorphone for inpatient pediatric burn wound care analgesia. *J Burn Care Rehabil* 1998;19:516-21.
456. Sharar SR, Carrougher GJ, Selzer K et al. Comparison of oral transmucosal fentanyl citrate and oral oxycodone for pediatric outpatient wound care. *J Burn Care Rehabil* 2002;23:27-31
457. Mahar PJ, Rana JA, Kennedy CS et al. Randomized clinical trial of oral transmucosal fentanyl citrate versus intravenous morphine sulfate for initial control of pain in children with extremity injuries. *Pediatr Emerg Care* 2007;23:544-8

458. Wheeler M, Birmingham PK, Dsida RM et al. Uptake pharmacokinetics of the Fentanyl Oralet in children scheduled for central venous access removal: implications for the timing of initiating painful procedures. *Pediatric Anaesthesia* 2002;12:594-9.
459. Zeppetella G. Sublingual fentanyl citrate for cancer-related breakthrough pain: a pilot study. *Palliative Medicine* 2001;15:323-8.
460. Escudero C et al. The medical management of arrhythmias. *Current Treatment Options in Cardiovascular Medicine*. 2012 Oct; 14(5): 455-72.
461. Escudero C et al. Overview of antiarrhythmic drug therapy for supraventricular tachycardia in children. *Progress in Pediatric Cardiology* 2013; 35 (1): 55-63.
462. Patel NH et al. Evaluation and management of pediatric hypertensive crises: hypertensive urgency and hypertensive emergencies. *Open Access Emerg Med* 2012; 4: 85-92.
463. Delgado MR et al. Practice Parameter: Pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review). *Neurology* 2010; 74: 336-343.
464. Klein EJ, Brown JC, Kobayashi A et al. A randomized clinical trial comparing oral, aerosolized intranasal, and aerosolized buccal midazolam. *Ann Emerg Med* 2011;58:323-9.
465. Jazz Pharmaceuticals Ireland Limited. Defitelio™ Product Monograph. 10 July 2017.
466. Richardson PG, Riches ML, Kernana NA et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. *Blood* 2016;127:1656-65
467. Richardson PG et al. Earlier defibrotide initiation post-diagnosis of veno-occlusive/sinusoidal obstruction syndrome improves day +100 survival following haematopoietic stem cell transplantation. *Br J Haematol* 2017. 178(1): 112-118.
468. Zulanga M. Chylothorax after surgery for congenital heart disease. *Current Opinion in Pediatrics* 2012. 24(3): 291-4.
469. Demirkilek H, Shah P, Bhushan Arya V et al. Long-term follow-up of children with congenital hyperinsulinism on octreotide therapy. *J Clin Endocrinol Metab* 2014;99:3660-7.
470. Eroglu Y, Emerick KM, Whitingon PF et al. Octreotide therapy for control of acute gastrointestinal bleeding in children. *J Pediatr Gastroenterol Nutr* 2004;38:41-7
471. Wise-Faberowski L et al. Perioperative management of diabetes insipidus in children. *J Neurosurg Anesthesiol* 2004; 16:220-3
472. Horimoto Y, Tomie H, Hanzawa K et al. Scopolamine patch reduces postoperative emesis in paediatric patients following strabismus surgery. *Can J Anesthesia* 1991;38:441-4
473. Lewis DW, Fontana C, Mehallick LK et al. Transdermal scopolamine for reduction of drooling in developmentally delayed children. *Developmental medicine and child neurology* 1994;36:484-6
474. Zelenitsky S, Ariano R, Harding G, Forrest A. Evaluating ciprofloxacin dosing for *Pseudomonas aeruginosa* infection by using clinical outcome-based Monte Carlo simulations. *Antimicrob Agents Chemother* 2005;10:4009-14.
475. Crash-2 trial collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant hemorrhage (CRASH-2): a randomized placebo-controlled trial. *Lancet* 2010;376:23-32
476. Eckert MJ, Wetin TM, Tyner SD et al. Tranexamic acid administration to pediatric trauma patients in the combat setting: The pediatric trauma and tranexamic acid study (PED-TRAX) *J Trauma Acute Care Surg* 2014;77:852-8.
477. Faraoni D, Goobie SM. The efficacy of antifibrinolytic drugs in children undergoing noncardiac surgery: A systematic review of the literature. *Anesth Analg* 2014;118:628-36
478. Skeens M et al. Twice daily I.V. bolus tacrolimus infusion for GVHD prophylaxis in children undergoing stem cell transplantation. *Bone Marrow Transplant* 2012. 47(11): 1415-8.
479. Ammar A, Mahmoud K, Kasemy Z. A comparison of sugammadex and neostigmine for reversal of rocuronium-induced neuromuscular blockade in children. *Acta Anaesthesiologica Scandinavica*. 2017;61(4):374-380.
480. Won YJ, Lim BG, Lee DK, Kim H, Kong H, Lee IO. Sugammadex for reversal of rocuronium-induced neuromuscular blockade in pediatric patients A systematic review and meta-analysis. *Medicine*. 2016;95(34)
481. Godwin SA, Burton JH, Gerardo CJ, et al. Clinical policy: procedural sedation and analgesia in the emergency department. *Ann Emerg Med*. 2014;63(2):247-258. [PubMed 24438649]
482. Chidambaran V et al. Propofol: a review of its role in pediatric anesthesia and sedation. *CNS Drugs* 2015; 29(7): 543-563.

483. Fujita M, Sato K, Nishioka H, Sakai F. Oral sumatriptan for migraine in children and adolescents: a randomized, multicenter, placebo-controlled, parallel group study. **Cephalalgia**. 2014 **Apr**;34(5):365-75
484. Firazyr® (icatibant) [Health Canada Product Monograph]. Shire Orphan Therapies, LLC. Lexington, MA. Last revision: November 19, 2015.
485. Farkas H et al. Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema. *J Allergy Clin Immunol Pract*. 2017 Nov - Dec;5(6):1671-1678.e2
486. Flank J et al. Olanzapine for treatment and prevention of acute chemotherapy-induced vomiting in children: A retrospective multi-center review. *Pediatr Blood Cancer* 2015; 72: 496-501.
487. Belle DJ, Ernest CS, Sauer JM, Smith BP, Thomasson HR, Witcher JW. Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. *J Clin Pharmacol*. 2002 Nov;42(11):1219-27
488. Ostinelli EG, Brooke-Powney MJ, Li X, Adams CE. Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). *Cochrane Database Syst Rev*. 2017 Jul 31;7(7):CD009377
489. Naik RD, Sreenivas V, Singh V et al. Olanzapine for the prevention of vomiting in children and adolescents receiving highly emetogenic chemotherapy: Investigator-initiated, randomized, open-label trial. *J Clin Oncol* 2020;38:3785-93
490. Radhakrishnan V, Pai V, Rajaraman S et al. Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced vomiting in children: An open-label, randomized phase 3 trial
491. Luc QN, Querubin J. Clinical Management of Dystonia in Childhood. *Paediatr Drugs*. 2017 Oct;19(5):447-461.
492. Goyal V, Laisram N, Wadhwa RK, Kothari SY. Prospective randomized study of oral diazepam and baclofen on spasticity in cerebral palsy. *J Clin Diagn Res*. 2016;10(6) :RC01-RC5.
493. Lubsch L, Habersang R, Haase M, Luedtke S. Oral baclofen and clonidine for treatment of spasticity in children. *J Child Neurol*. 2006;21(12):1090-1092.
494. Scheinberg A, Hall K, Lam LT, O'Flaherty S. Oral baclofen in children with cerebral palsy: a double-blind cross-over pilot study. *J Paediatr Child Health*. 2006;42(11):715-20.
495. Krause T et al. Dantrolene--a review of its pharmacology, therapeutic use and new developments. *Anaesthesia*. 2004
496. Riaz S, Kraeva N, Hopkins PM. Updated guide for the management of malignant hyperthermia. *Can J Anaesth*. 2018 Jun;65(6):709-721
497. Oleszek JL and Davidson LT. Spasticity. In Kliegman RM and St. Geme J, eds. *Nelson Textbook of Pediatrics*. 21st ed. Philadelphia, PA: Saunders Elsevier; 2020
498. Berlucchi M, Valetti L, Parrinello G, et al, "Long-Term Follow-Up of Children Undergoing Topical Intranasal Steroid Therapy For Adenoidal Hypertrophy," *Int J Pediatr Otorhinolaryngol*, 2008, 72(8):1171-5
499. Caffarelli C, Paravati F, El Hachem M, et al. Management of chronic urticaria in children: a clinical guideline. *Ital J Pediatr*. 2019;45(1):101
500. Pathirana S, Jayawardena S, Meeves S, Thompson GA. Brompheniramine and Chlorpheniramine Pharmacokinetics Following Single-Dose Oral Administration in Children Aged 2 to 17 Years. *J Clin Pharmacol*. 2018 Apr;58(4):494-503
501. Parisi GF et al. Cetirizine use in childhood: an update of a friendly 30-year drug. *Clin Mol Allergy*. 2020 Feb 26;18:2.
502. Silverman E, Mouy R, Spiegel L, et al; Leflunomide in Juvenile Rheumatoid Arthritis (JRA) Investigator Group. Leflunomide or methotrexate for juvenile rheumatoid arthritis. *N Engl J Med*. 2005;352(16):1655-1666
503. Dahl SG. Pharmacokinetics of methotrimprazine after single and multiple doses. *Clin Pharmacol Ther*. 1976 Apr;19(4):435-42
504. US Food & Drug Administration. New Pediatric Labeling Information Database – Detail (Trade name: Orencia) [Internet]. Maryland: US Food & Drug Administration; 2017 [Dec 2020]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125118s2111b1.pdf.
505. Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of paediatric ulcerative colitis, part 1: ambulatory care-an evidence-based guideline from European Crohn's and Colitis

- Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. *J Pediatr Gastroenterol Nutr*. 2018;67(2):257-291.
506. Hashkes PJ, Laxer RM. Medical treatment of juvenile idiopathic arthritis. *JAMA*. 2005;294(13):1671-1684.
507. Petty RE, Laxer RM, Lindsley CB, Wedderburn LR. *Textbook of Pediatric Rheumatology*. 7th ed. Elsevier; 2016
508. Sandhu BK, Fell JME, Beattie RM, et al. Guidelines for the management of inflammatory bowel disease in children in the United Kingdom. *JPGN*. 2010;50:S1-S13.
509. Colman RJ et al. Methotrexate for the treatment of pediatric Crohn's disease: a systematic review and meta-analysis. *Inflamm Bowel Dis* 2018; 24: 2135-2141.
510. Product Monograph: ACTEMRA tocilizumab solution for injection. Hoffmann-La Roche Limited. Mississauga, Ontario 2021.
511. Griffiths B, Kew KM. Intravenous magnesium sulfate for treating children with acute asthma in the emergency department. *Cochrane Database Syst Rev*. 2016; (4):CD011050.
512. Elbe D, Macbride A, Reddy D. Focus on Lisdexamfetamine: A Review of its use in Child and Adolescent Psychiatry. *J Can Acad Child Adolesc Psychiatry* 2010;19:303-14
513. Elbe D, Reddy D. Focus on Guanfacine Extended-release: A Review of its Use in Child and Adolescent Psychiatry. *J Can Acad Child Adolesc Psychiatry* 2014;23:48-60.
514. Theurich S, Fischmann H, Chakupurakal G et al. Anti-thymocyte globulins for post-transplant graft-versus host disease prophylaxis- A systematic review and meta-analysis. *Crit Rev Oncol Hematol* 2013;88:178-86
515. Patel P, Leeder JS, Piquette-Miller M et al. Aprepitant and fosaprepitant drug interactions: a systematic review. *Br J Clin Pharmacol* 2017;83:2148-62
516. Gouin S, Vo TT, Roy M et al. Oral dimenhydrinate versus placebo in children with gastroenteritis: a randomized controlled trial. *Pediatric* 2012;129:1050-5
517. Kranke P, Morin M, Roewer N et al. Dimenhydrinate for prophylaxis of postoperative nausea and vomiting: a meta-analysis of randomized controlled trials. *Acta Scand* 2002;46:238-44.
518. Sung L, Nathan PC, Lange B et al. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials. *J Clin Oncol* 2004;22:3350-6
519. Ramsey LB, Balis FM, O'Brien M et al. Consensus guideline for use of glucarpidase in patients with high-dose methotrexate induced acute kidney injury and delayed methotrexate clearance. *Oncologist* 2018;23:52-61
520. Polito S, MacDonal R, Romanick M et al. Safety and efficacy of nabilone for acute chemotherapy-induced vomiting prophylaxis in pediatric patients: A multicenter, retrospective review. *Pediatr Blood Cancer* 2018;65:e27374
521. Khalil SN, Roth AG, Cohen IT et al. Double-blind comparison of intravenous ondansetron and placebo for preventing post-operative emesis in 1- to 24-month-old pediatric patients after surgery under general anesthesia. *Anesth Analg* 2005;101:356-61
522. Gan T, Belani K, Bergese S et al. Fourth consensus guidelines for the management of postoperative nausea and vomiting. *Anesth Analg* 2020;131:411-48
523. Flank J, Robinson PD, Holdsworth M, Phillips R, Portwine C et al. Guideline for the treatment of breakthrough and the prevention of refractory chemotherapy –induced nausea and vomiting in children with cancer. *Pediatr Blood Cancer* 2016;63:1144-51
524. Kovacs G, Wachtel AE, Basharova EV, Spinelli T, Nicolas P, Kabickova E. Palonosetron versus ondansetron for prevention of chemotherapy induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study. *Lancet Oncol*. 2016;17(3):332–344.
525. Wang J, Mehrotra N, Kim I et al. Exposure-response of palonosetron for prevention of chemotherapy-induced nausea and vomiting in pediatric patients. *J Pediatr Gastroenterol Nutr* 2016;63:412-6
526. Kruizinga MD, Bresters D, Smiers FJ et al. The use of intravenous pentamidine for the prophylaxis of *Pneumocystis pneumonia* in pediatric patients. *Pediatr Blood Cancer* 2017;64:e26453

527. Quinn M, Fannin JT, Sciasci J et al. Pentamidine for prophylaxis against *Pneumocystis jirovecii* pneumonia in pediatric oncology patient receiving immunosuppressive chemotherapy. *Antimicrobial Agents Chemother* 2018;62:e00173-18
528. Children's Oncology Group Leukemia Guidelines
529. Children's Oncology Group Long-Term Follow-up Guidelines
530. Sun et al. Dexrazoxane improves cardiac autonomic function in epirubicin-treated breast cancer patients with type 2 diabetes. *Medicine (Baltimore)* 2016;95:e5228
531. De Giorgi U et al. High-dose epirubicin, preceded by dexrazoxane, given in combination with paclitaxel plus filgrastim provides an effective mobilizing regimen to support three courses of high-dose dense chemotherapy in patient with high-risk stage II-IIIa breast cancer. *Bone Marrow Transplant* 2003;32:251-5
532. Vachhani P et al. Dexrazoxane for cardioprotection in older adults with acute myeloid leukemia. *Leuk Res Rep.* 2017; 7: 36–39
533. Brar et al. Management and Appropriate Use of Diazoxide in Infants and Children with Hyperinsulinism. *J Clin Endocrinol Metab.* 2020 Dec 1;105(12)
534. Kuskonmaz B, Yalcin S, Kucukbayrak O et al. The effect of glutamine supplementation on hematopoietic stem cell transplant outcome in children: A case–control study. *Pediatr Transplantation* 2008; 12: 47–51.
535. Ward E, Smith M, Henderson M et al. The effect of high-dose enteral glutamine on the incidence and severity of mucositis in paediatric oncology patients. *Eur J Clin Nutr* 2009;63:134-40
536. Baskin JL, Pui CH, Reiss U et al. Management of occlusion and thrombosis associated with long-term indwelling central venous catheters. *Lancet* 2009;374:159-69
537. Monagle P, Newall F. Management of thrombosis in children and neonates: Practical use of anticoagulants in children. *Hematology Am Soc Hematol Educ Program* 2018;399-404
538. Soman T, Rafay MF, Hune S et al. The risks and safety of clopidogrel in pediatric arterial ischemic stroke. *Stroke* 2006;37:1120-2
539. Brittenham GM. Iron-chelating therapy for transfusional iron overload. *N Engl J Med* 2011;364:146-56
540. Huang JY, Monagle P, Massicotte PM. Antithrombotic therapies in children on durable Ventricular Assist Devices: A literature review. *Thrombosis Research* 2018;172:194-203
541. Mitchell JP, Nagel MW. Particle Size Analysis of Aerosols from Medicinal Inhalers. *Kona Powder and Particle Journal.* Volume 22. Sep 21, 2004.
542. Rameshkumar R et al. Randomized clinical trial of 20% mannitol versus hypertonic saline in children with raised intracranial pressure due to acute CNS infection. *Pediatr Crit Care Med* 2020;21:1071-80
543. Kumari N et al. Comparative assessment of hypertonic saline versus mannitol in the treatment of raised intracranial tension in children. *EJMCM* 2020;7:3968-74
544. Shi J et al. Hypertonic saline and mannitol in patients with traumatic brain injury. A systematic and meta-analysis. *Medicine (Baltimore)* 2020;99:e21655
545. Oskoui M. et al. Practice guideline update summary: Acute treatment of migraine in children and adolescents. *Neurology* 2019;93:489-499
546. Wang G; Tan T; Liu Y; Hong P. Drugs for acute attack of pediatric migraine: A network meta-analysis of randomized controlled trials. *Clinical Neurology and Neurosurgery* 2020;195:105853
547. Afshar M. Review of dextromethorphan administration in 18 patients with subacute methotrexate central nervous system toxicity. *Pediatr Neurol* 2014;50:625-9
548. Athale U, Hijiya N, Patterson BC et al. Management of chronic myeloid leukemia in children and adolescents: Recommendations from the Children's Oncology Group CML Working Group. *Pediatr Blood Cancer* 2019;66:e27827
549. Children's Oncology Group. A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid AAML1331
550. National Heart, Lung, and Blood Institute (NHLBI). Evidence-based management of sickle cell disease: expert panel report, 2014. Bethesda, MD: National Institutes of Health; 2014. <http://www.nhlbi.nih.gov/health-pro/guidelines/sickle-cell-disease-guidelines>. Accessed August 13, 2021.
551. TauroSept® Product Monograph (Geistlich Pharma)

552. Chu HP, Brind J, Tomar R, Hill S. Significant reduction in central venous catheter-related bloodstream infections in children on HPN after starting treatment with taurididine lock. *J Pediatr Gastroenterol Nutr* 2012;55(4):403-7.
553. Hulshof EC, Hanff LM, Olieman J et al. Taurididine in pediatric home parenteral nutrition patients. *Pediatr Infect Dis J* 2017;36(2):233-5.
554. Trottier et al. Canadian Pediatric Society Position Statement: Managing pain and distress in children undergoing brief diagnostic and therapeutic procedures. *Paediatr Child Health* 2019 24(8):509-521.
555. AAP COMMITTEE ON FETUS AND NEWBORN and SECTION ON ANESTHESIOLOGY AND PAIN MEDICINE. Prevention and Management of Procedural Pain in the Neonate: An Update. *Pediatrics*. 2016;137(2):e20154271
556. Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, et al. Evidence-based guideline: Treatment of convulsive status epilepticus in children and adults: Report of the Guideline Committee of the American Epilepsy Society. *Epilepsy Curr*. 2016;16(1):48-61.
557. McKenzie KC, Hahn CD, Friedman JN. Canadian Pediatric Society position statement: Emergency management of the paediatric patient with convulsive status epilepticus. *Paediatr Child Health* 2021;26(1):50-57
558. Kumar A, Reljic T, Hamadani M et al. Antithymocyte globulin for graft-versus-host disease prophylaxis: an updated systematic review and meta-analysis. *Bone Marrow Transplant* 2019;54:1094-1106
559. Scheinberg P, Nunez O, Weinstein B et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. *New Engl J Med* 2011;365:430-8
560. BC Children's Hospital. Division of Hematology, Oncology, and Blood and Marrow Transplant. BMT Supportive Care Guidelines. Nov 12, 2019.
561. BC Transplant Clinical Guidelines for Transplant Medications. 2019. <http://www.transplant.bc.ca/Documents/Health%20Professionals/Clinical%20guidelines/Clinical%20Guidelines%20for%20Transplant%20Medications.pdf>
562. Vukadinović D, Scholz SS, Messerli FH, et al. Peripheral edema and headache associated with amlodipine treatment: a meta-analysis of randomized, placebo-controlled trials. *J Hypertens*. 2019;37(10):2093–2103.
563. Vincent J, Harris SI, Foulds G, Dogolo LC, Willavize S, Friedman HL. Lack of effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of amlodipine. *Br J Clin Pharmacol*. 2000;50(5):455-463.
564. Josefsson M, Ahlner J. Amlodipine and grapefruit juice. *Br J Clin Pharmacol*. 2002;53(4):405
565. Baracco, R. A Practical Guide to the Management of Severe Hypertension in Children. *Pediatr Drugs* 2020;22, 13–20
566. Suresh S, et al. The European Society of Regional Anaesthesia and Pain Therapy/American Society of Regional Anesthesia and Pain Medicine recommendations on local anesthetics and adjuvants dosage in pediatric regional anesthesia. *Reg Anesth Pain Med* 2018;43:211-6.
567. Suresh S, Polaner D, Cote CJ. Regional anesthesia. In: Cote CJ, Lerman JB, Anderson BJ, eds. *Pract Anesth Infants Child*. 6th ed. Philadelphia, PA: Elsevier, Inc; 2019:941-87.
568. Tsui B, Boretsky K, Berde C. Maximum recommended dosage of ropivacaine and bupivacaine for pediatric regional anesthesia. *Reg Anesth and Pain Med* 2018;43(8):895-6.
569. Bosenberg AT, Thomas J, Lopez T, Huledal G, Jeppsson L, Larsson LE. Plasma concentrations of ropivacaine following a single-shot caudal block of 1, 2 or 3 mg/kg in children. *Acta Anaesthesiol Scand*. 2001;45:1276-80.
570. NYSORA – Regional Anesthesia in Pediatric Patients: General Considerations. Available: <https://www.nysora.com/foundations-of-regional-anesthesia/sub-specialties/pediatric-anesthesia/regional-anesthesia-pediatric-patients-general-considerations/>
571. Berde CB, Strichartz GR. Local anesthetics. In: Miller RD, editor. *Miller's Anesthesia*. Eighth edition. Philadelphia: Elsevier; 2015.
572. Mina R et al. Consensus treatment plans for induction therapy of newly-diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. *Arthritis Care Res*. 2012 March; 64(3): 375–383.

573. EUVAS protocol: De Groot K et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody– associated vasculitis: a randomized trial. *Ann Intern Med.* 2009;150: 670-680
574. <http://www.bcrenal.ca/resource-gallery/Documents/Supporting%20Evidence%20Document-Cyclophosphamide%20Protocol%20for%20MCD%20and%20FSGS.pdf>
575. Reddy S, Kamath N. Clinical approach to renal tubular acidosis in children. *Karnataka Pediatric Journal.* 2021 Jan 25;35(2):88-94
576. Bupivacaine Local Anesthetic, solution [prescribing information]. Kirkland, Quebec: Pfizer Canada ULC; February 2019
577. Chen Z, Lin M, Huang Z et al. Efficacy of chloral hydrate oral solution for sedation in pediatrics: a systematic review and meta-analysis. *Drug Design, Development and Therapy* 2019;13:2643-53
578. Fong CY, Tay CG, Ong LC et al. Chloral hydrate as a sedating agent for neurodiagnostic procedures in children. *Cochrane Database of Systematic Reviews* 2017, Issue 11. Art No: CD011786
579. Thigpen JC et al. Opioids: a review of pharmacokinetics and pharmacodynamics in neonates, infants, and children. *Eur J Drug Metab Pharmacokinet* 2019; 44(5): 591-609
580. Hegenbarth MA, Committee on Drugs. Preparing for pediatric emergencies: Drugs to consider. *Pediatrics* 2008;121(2):433-43.
581. Heilbrunn BR et al. A retrospective comparison of ketamine dosing regimens for pediatric procedural sedation. *Eur J Emerg Med* 2015; 22(2): 111-116
582. McNichol ED et al. Ketorolac for postoperative pain in children. *Cochrane Database Syst Rev* 2018; 7(7): CD012294
583. Miller JL, Hagemann TM. Use of pure opioid antagonists for management of opioid-induced pruritus. *Am J Health Syst Pharm* 2011; 68(15): 1419-1425.
584. Kaul et al. Use of gabapentin and pregabalin for pruritus and neuropathic pain associated with major burn injury: A retrospective chart review. *Burns* 2018;44(2):414-422.
585. Arnold LM et al. Safety and efficacy of pregabalin in adolescents with fibromyalgia: a randomized, double-blind, placebo-controlled trial and a 6-month open-label extension study. *Pediatr Rheumatol Online J* 2016;14(1):46
586. Matsui M et al. Reversibility of Rocuronium-Induced Deep Neuromuscular Block with Sugammadex in Infants and Children—A Randomized Stud. *Biol Pharm Bull* 2019;42:1637-1640.
587. Ferric Derisomaltose (iron isomaltoside) Product Monograph. Pfizer Canada. Kirkland, Canada. Sep 16, 2021 https://pdf.hres.ca/dpd_pm/00062976.PDF
588. Lane, Roni D, et al. Amiodarone for the Emergency Care of Children, *Pediatric Emergency Care: May 2010 - Volume 26 - Issue 5 – p382-389* doi: 10.1097/PEC.0b013e3181ddd2d6
589. January CT, Wann S, Alpert JS et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. *Circulation* 2014;130:e199-267
590. Cunningham T, Uzun O, Morris R, Franciosi S, Wong A, Jeremiasen I, Sherwin E, Sanatani S. The Safety and Effectiveness of Flecainide in Children in the Current Era. *Pediatr Cardiol.* 2017 Dec;38(8):1633-1638. doi: 10.1007/s00246-017-1707-5. Epub 2017 Aug 24. PMID: 28840327
591. Sheno, Rohit P., et al. "Drugs Used to Treat Pediatric Emergencies." *American Academy of Pediatrics, American Academy of Pediatrics*, 1 Jan. 2020, pediatrics.aappublications.org/content/145/1/e20193450
592. Singh M, McKenzie K, Hudak ML, Gehi AK, and Ferns SJ (2021). Electrophysiological effects and clinical utility of propafenone in children. *Cardiology in the Young*, page 1 of 5. doi: 10.1017/S1047951121002857
593. Waldman AR, Ahluwalia J, Udkoff J, et al. Atopic dermatitis. *Pediatr Rev* 2018;39(4):180-191.
594. Yang EJ, Sekhon S, Sanchez IM, et al. Recent developments in atopic dermatitis. *Pediatrics* 2018;142(4): e20181102
595. Tollefson MM, Bruckner AL. Atopic dermatitis: skin-directed management. *Pediatrics* 2014;134(6):e1735-e1744.
596. Weinstein M, Barber K, Bergman J, et al. (2018). Atopic dermatitis: a practical guide to management. Retrieved from https://eczemahelp.ca/wp-content/uploads/2019/03/ESC_AD_Practical-Guide-to-Management-for-HCP_2019.pdf
597. Eichenfield LF, Krakowski AC, Piggott C, et al. Evidence-based recommendations for the diagnosis and treatment of pediatric acne. *Pediatrics* 2013;131:S163-S186.

598. Ashton R, Weinstein M. Acne vulgaris in the pediatric patient. *Pediatr Rev* 2019;40(11):577-589.
599. Cummings C, Finlay JC, MacDonald NE. Head lice infestations: a clinical update (Canadian Paediatric Society Practice Point). *Paediatr Child Health* 2018;23(1):e18-24.
600. Banerji A. Scabies (Canadian Paediatric Society Position Statement). *Paediatr Child Health* 2015;20(7):395-8.
601. Trottier ED, Dore-Bergeron MJ, Chauvin-Kimoff L, et al. Managing pain and distress in children undergoing brief diagnostic and therapeutic procedures (Canadian Pediatric Society Position Statement). *Paediatr Child Health* 2019;24(8):509-21.
602. Health Canada (2016). Summary safety review – viscous lidocaine 2% - assessing the potential risk of severe side effects in infants and young children. Accessed from: <https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/summary-safety-review-viscous-lidocaine-assessing-potential-risk-effects-infants-young-children.html#:~:text=Health%20Canada%20carried%20out%20a%20safety%20review%20to,used%20for%20teething%20pain%20in%20infants%20and%20children>.
603. Canadian Pediatric Society (2019 June). Antifungal agents for common outpatient paediatric infections. Retrieved from <https://www.cps.ca/documents/position/antifungal-agents-common-infections>
604. BC Centre for Disease Control (2020). Non-certified practice decision support tool: vulvovaginal candidiasis (VVC). Retrieved from <http://www.bccdc.ca/resource-gallery/Documents/Communicable-Disease-Manual/Chapter%205%20-%20STI/Non-certified%20VVC%20DST.pdf>
605. Van Schalkwyk J, Yudin MH. SOGC clinical practice guideline – vulvovaginitis: screening for and management of trichomoniasis, vulvovaginal candidiasis, and bacterial vaginosis. *J Obstet Gynaecol Can* 2015;37(3):266-274.
606. Patel P, Olteanu A, Cabral S et al. Dexamethasone dosing for prevention of acute chemotherapy-induced vomiting in pediatric patients: A systematic review. *Pediatr Blood Cancer* 2020;67:e28716
607. Gates A, Gates M, Vandermeer B, Johnson C, Hartling L, Johnson DW, Klassen TP. Glucocorticoids for croup in children. *Cochrane Database Syst Rev*. 2018 Aug 22;8(8)
608. Le Saux N, Robinson JL; Canadian Paediatric Society Infectious Diseases and Immunization Committee. Uncomplicated pneumonia in healthy Canadian children and youth: Practice points for management. Oct 31, 2018. <https://cps.ca/documents/position/pneumonia-management-children-youth> [accessed Apr 11, 2022]
609. Tompkins MG and Pettit R. Beyond the Guidelines: Treatment of Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis. *Ann Pharmacother*. 2022;56(2):181-192
610. Floto RA, Olivier KN, Saiman L, et al. US CFF and ECFS consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. *Thorax* 2016;71:i1-i22
611. Green C et al. Symptomatic fever management in children: A systematic review of national and international guidelines. *PLOS ONE*, June 17, 2021
612. Lehrnbecher T, Fisher BT, Phillips B et al. Clinical practice guideline for systemic antifungal prophylaxis in pediatric patients with cancer and hematopoietic stem-cell transplantation recipients. *J Clin Oncol* 2020;38
613. Brownell JN et al. Growth and Nutrition in Cystic Fibrosis. *Semin Respir Crit Care Med* 2019;40:775-791
614. Le Saux, N. Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Diagnosis and management of acute osteoarticular infections in children. *Paediatr Child Health* 2018;23:336-43
615. Woods CR, Bradley JS, Chatterjee A et al. Clinical Practice Guideline by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America: 2021 Guideline on Diagnosis and Management of Acute Hematogenous Osteomyelitis in Pediatrics. *J Pediatr Infect Dis Soc* 2021. Accessed Apr 26, 2022 <https://www.idsociety.org/globalassets/idsa/practice-guidelines/piab027.pdf>

616. Zobell JT, Waters CD, Young DC et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. Cephalosporins and penicillins. *Pediatr Pulmonol* 2013;48:107-22.
617. Shoji K, Bradley JS, Reed MD et al. Population pharmacokinetic assessment and pharmacodynamics implications of pediatric cefepime dosing for susceptible-dose dependent organisms. *Antimicrobial Agents and Chemotherapy* 2016;60:2150-6
618. Inaba H, Gaur AH, Cao X et al. Feasibility, efficacy, and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia. *Cancer* 2014;120:1985-92
619. DeRonde KJ, Giroto JE, Nicolau DP. Management of pediatric acute hematogenous osteomyelitis part II: A focus on methicillin-resistant *Staphylococcus aureus*, current and emerging therapies. *Pharmacotherapy* 2018;38:1021-37
620. Erythromycin ophthalmic ointment. Prescribing Information. Steri-Med Pharma Inc. Upton, Quebec. May 3, 2021. Accessed Apr 27, 2022 https://pdf.hres.ca/dpd_pm/00061356.PDF
621. Ljungman P, de la Camara R, Robin C, et al, on behalf of the 2017 European Conference on Infections in Leukaemia group. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). *Lancet Infect Dis* 2019; published online May 29, 2019 [http://dx.doi.org/10.1016/S1473-3099\(19\)30107-0](http://dx.doi.org/10.1016/S1473-3099(19)30107-0)
622. Reusser P, Einsele H, Lee J et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. *Blood* 2002;99:1159-64
623. Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf. Section accessed August 6, 2019, Page GG-7, Table 3.
624. Camargo JF, Anderson AD, Rosa R, Kimble E, Komanduri KV, Morris MI. Use of maintenance therapy and incidence of recurrent Cytomegalovirus DNAemia among allogeneic hematopoietic cell transplant recipients. *Transpl Infect Dis*. 2019 Apr;21(2):e13054. doi: 10.1111/tid.13054. Epub 2019 Feb 11. PubMed PMID: 30689300.
625. Razonable RR, Humar A; AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplantation. *Am J Transplant*. 2013 Mar;13 Suppl 4:93-106. doi: 10.1111/ajt.12103. PubMed PMID: 23465003
626. Alexander S, Fisher BT, Gaur AH et al. Effect of levofloxacin prophylaxis on bacteremia in children with acute leukemia or undergoing hematopoietic stem cell transplantation. *JAMA* 2018;320:995-1004
627. Zobell JT, Young DC, Waters CD, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems. *Pediatr Pulmonol* 2012;47(12):1147-58.
628. Allen UD. Canadian Paediatric Society, Infectious Diseases and Immunization Committee. The use of antiviral drugs for influenza: Guidance for practitioners. Oct 9, 2018. Accessed Apr 28, 2022 <https://cps.ca/documents/position/antiviral-drugs-for-influenza>
629. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: Treatment of drug-susceptible tuberculosis. *Clin Infect Dis* 2016;63:e147-95
630. Young DC, Zobell JT, Stockmann C, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides. *Pediatr Pulmonol* 2013;48(11):1047-61
631. Tomblyn M, Chiller T, Einsele H et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. *Biol Blood Marrow Transplant* 2009;15:1143-238
632. Friberg LE, Ravva P, Karlsson MO, Liu P. Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults. *Antimicrob Agents Chemother*. 2012;56(6):3032-3042
633. Bartelink IH, Wolfs T, Jonker M et al. Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients. *Antimicrobial Agents and Chemotherapy* 2013;57:235-40

634. Canadian Paediatric Society Position Statement. Emergency treatment of anaphylaxis in infants and children. *Paediatr Child Health* 2011; 16(1):35-40 (<https://cps.ca/documents/position/emergency-treatment-anaphylaxis>; Reaffirmed Feb 28, 2018)
635. Wenning LA et al. Pharmacokinetics of Famotidine in Infants. *Clin Pharmacokinet* 2005; 44(4): 395-406.
636. Orenstein SR et al. Famotidine for Infant Gastro-esophageal Reflux: a Multi-centre, Randomized, Placebo-controlled, Withdrawal Trial. *Aliment Pharmacol Ther* 2003; 17: 1097-1107.
637. Baird DC et al. Diagnosis and Treatment of Gastroesophageal Reflux in Infants and Children. *Am Fam Physician*. 2015 Oct 15;92(8):705-717
638. The Canadian Haemoglobinopathy Association . Consensus statement on the care of patients with sickle cell disease in Canada. 2015
639. Van der Dijs FP, Fokkema MR, Dijck-Brouwer DA, et al. Optimization of Folic Acid, Vitamin B12, and Vitamin B6 Supplements in Pediatric Patients with Sickle Cell Disease. *Am J Hematol*. 2002;69:239-46.
640. BCGuidelines.ca: Palliative Care for the Patient with Incurable Cancer or Advanced Disease; Part 2: Pain and Symptom Management – Dyspnea: Appendix A-Medications Used in Palliative Care for Dyspnea and Respiratory Secretions (2017)
641. Jassal SS et al. APPM Master Formulary (5th Edition). The Association of Pediatric Palliative Medicine Master Formulary; 2020, pages 65-66.
642. Hauer J et al. Pediatric Pain and Symptom Management Guidelines. Dana Farber Cancer Institute/Boston Children's Hospital Pediatric Advanced Care Team 2014
643. Health Canada Guidance document - Nonprescription oral adult expectorant cough and cold labelling standard Effective date: 2014/05/30
644. Parisi GF et al. Antihistamines in children and adolescents: A practical update. *Allergol Immunopathol (Madr)*. 2020; 48(6):753-762
645. Anderson S, Farrington E. Magnesium Treatment in Pediatric Patients. *J Ped HC*, 2021; 35(5):564-571
646. Robinson JL, Le Saux N. Canadian Paediatric Society, Infectious Diseases and Immunization Committee, Preventing hospitalizations for respiratory syncytial virus infection, *Paediatr & Child Health*, 2015;20(6): 321–326, Reaffirmed Jan 1, 2021.
647. Coughlin CR et al. Consensus Guidelines For the Diagnosis and Management of Pyridoxine-Dependent Epilepsy Due to α -Aminoacidic Semialdehyde Dehydrogenase Deficiency. *J Inherit Metab Dis*. 2021;44:178-192. (DOI: 10.1002/jimd.12332)
648. Health Canada Public Advisory, Status of ranitidine drugs in Canada. July 23, 2020. (<https://recalls-rappels.canada.ca/en/alert-recall/status-ranitidine-drugs-canada>)
649. DaSilva J et al. ASPEN Consensus Recommendations for Refeeding Syndrome. *Nutr Clin Prac*. April 2020; 35(2):178-
650. Turck D et al. ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis. *Clin Nutr*. 2016;35(3):557-77
651. Abman SH, Hansmann G, Archer SL, Ivy DD, Adatia I, Chung WK, Hanna BD, Rosenzweig EB, Raj JU, Cornfield D, Stenmark KR, Steinhorn R, Thébaud B, Fineman JR, Kuehne T, Feinstein JA, Friedberg MK, Earing M, Barst RJ, Keller RL, Kinsella JP, Mullen M, Deterding R, Kulik T, Mallory G, Humpl T, Wessel DL; American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Surgery and Anesthesia; and the American Thoracic Society. Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society. *Circulation*. 2015 Nov 24;132(21):2037-99. doi: 10.1161/CIR.0000000000000329. Epub 2015 Nov 3. Erratum in: *Circulation*. 2016 Jan 26;133(4):e368. PMID: 26534956
652. Cartotto R. Topical antimicrobial agents for pediatric burns. *Burns & Trauma* 2017;5:33-40
653. Ratjen F et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicenter, randomized, double-blind, placebo-controlled trial. *Lancet Respir Med*. 2019;7:802-809.

654. Tiddens HAWM et al. The effect of inhaled hypertonic saline on lung structure in children aged 3-6 years with cystic fibrosis (SHIP-CT): a multicenter, randomized, double-blind controlled trial. *Lancet Respir Med*. S2213-2600(21)00546-4. doi: 10.1016/S2213-2600(21)00546-4
655. Lindor et al. High Dose Ursodeoxycholic Acid for the Treatment of Primary Sclerosing Cholangitis. *Hepatology*. 2009;50(3):808-814
656. Cheuk DKL, Chiang AKS, Ha SY et al. Interventions for prophylaxis of hepatic veno-occlusive disease in people undergoing haematopoietic stem cell transplantation. *Cochrane Database Syst Rev* 2015;27:CD009311
657. HIV/HCV Drug Therapy Guide. UHN- Toronto General Hospital, Immunodeficiency Clinic; 2016 [cited 2022 Jan 26]. Available from: <http://app.hivclinic.ca/>
658. ACOG Committee on Adolescent Health Care. Screening and management of bleeding disorders in adolescents with heavy menstrual bleeding. ACOG Committee Opinion No. 785. American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2019;134:e71–83.
659. Depo-Provera (medroxyprogesterone acetate) [Health Canada Product Monograph]. Pfizer Canada ULC. Kirkland, Quebec. Last revision: December 17, 2021.
660. Munro MG, Mainor N, Basu R, Brisinger M, Barreda L. Oral medroxyprogesterone acetate and combination oral contraceptives for acute uterine bleeding: a randomized controlled trial. *Obstet Gynecol*. 2006 Oct;108(4):924-9
661. ACOG Committee on Adolescent Health Care. Options for prevention and management of menstrual bleeding in adolescent patients undergoing cancer treatment. ACOG Committee Opinion No. 817. American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2021;137:e7–15.
662. Unger C. Hormone therapy for transgender patients. *Translational Andrology and Urology*, 2016;5(6):877-884
663. Canadian Paediatric and Adolescent Gynaecology and Obstetricians (CANPAGO) Committee. SOGC Clinical Practice Guideline No. 313-Menstrual Suppression in Special Circumstances. *J Obstet Gynaecol Can* 2019;41(2):e7–e17.
664. The Canadian Haemoglobinopathy Association . Consensus statement on the care of patients with sickle cell disease in Canada. 2015
665. van der Dijs FP, Fokkema MR, Dijck-Brouwer DA, et al. Optimization of Folic Acid, Vitamin B12, and Vitamin B6 Supplements in Pediatric Patients with Sickle Cell Disease. *Am J Hematol*. 2002;69:239-46.
666. Protocols for the treatment of hemophilia and von Willebrand disease. 3rd Ed. Georgia. Apr 2008. <http://www1.wfh.org/publication/files/pdf-1137.pdf>
667. Ben-Pazi H. Trihexyphenidyl improves motor function in children with dystonic cerebral palsy: a retrospective analysis. *J Child Neurol*. 2011;26(7):810-816.
668. Carranza-del Rio J, Clegg NJ, Moore A, Delgado MR. Use of trihexyphenidyl in children with cerebral palsy. *Pediatr Neurol*. 2011;44(3):202-206.
669. Rice J and Waugh MC, "Pilot Study on Trihexyphenidyl in the Treatment of Dystonia in Children With Cerebral Palsy," *Child Neurol*, 2009, 24(2):176-82.
670. Sanger TD, Bastian A, Brunstrom J, et al, "Prospective Open-Label Clinical Trial of Trihexyphenidyl in Children With Secondary Dystonia Due to Cerebral Palsy," *J Child Neurol*, 2007, 22(5):530-7.
671. Gilead Science Canada Inc VEKLURY Product Monograph, Health Canada April 22, 2022 https://pdf.hres.ca/dpd_pm/00065539.PDF
672. US Food and Drug Administration (FDA) Emergency Use Authorization Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of VEKLURY (remdesivir) https://www.samc.com/assets/documents/covid19/nursing/remdesivir_eua-hcp-fact-sheet-8-2020.pdf accessed May 2 2022
673. Rosenberg JB, Eisen LA. Eye care in the intensive care unit: Narrative review and meta-analysis. *Crit Care Med* 2008;36:3151-3155.
674. Soothe Lubricant Eye Ointment Night Time Dry Eye Therapy [Internet]. 2019 [cited 2020 Aug 11]. Available from: <https://www.sootheeyedrops.com/products/night-time.html>
675. Isopto Tears 0.5% [package insert]. ON, CAN; Alcon Canada Inc.; 2016
676. Isopto Tears 1% [package insert]. ON, CAN; Novartis Pharmaceuticals Canada Inc.; 2017

677. Tear-Gel Ophthalmic Liquid Gel [package insert]. QC, CAN: Bausch & Lomb Inc.; no publication date
678. Tears Plus [product packaging]. ON, CAN: Allergan; 2014
679. Refresh Polyvinyl Alcohol 1.4% Preservative Free. ON, CAN: Allergan; 2019
680. Clinical Guidelines: Care of Children with Cystic Fibrosis – Royal Brompton Hospital. 8th edition. 2020. Accessible at www.rbht.nhs.uk/childrencf
681. Turck D et al. ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children and adults with cystic fibrosis. *Clin Nutr.* 2016;35:557-577
682. Go CY, Mackay MT, Weiss SK, Stephens D, Adams-Webber T, Ashwal S, et al. Evidence-based guideline update: Medical treatment of infantile spasms. *Neurology.* 2012;78(24):1974-80
683. Heiskala H, Riikonen R, Santavuori P, Simell O, Airaksinen E, Nuutila A, et al. West syndrome: individualized ACTH therapy. *Brain Dev.* 1995;18(6):456-60
684. Amoxicillin Sodium and Potassium Clavulanate for Injection [product monograph]. Boucherville, Quebec (CA): Sandoz Canada Inc; 2020 [updated 2023 Jan 26; cited 2023 Mar 03]. Available from: https://pdf.hres.ca/dpd_pm/00069325.PDF
685. Carlier M, Noë M, De Waele JJ, et al. Population pharmacokinetics and dosing simulations of amoxicillin/clavulanic acid in critically ill patients. *J Antimicrob Chemother.* 2013 Jun 25;68:2600-2608
686. Child J, Chen X, Mistry RD, Somme S, MacBrayne C, Anderson PL, et al. Pharmacokinetic and Pharmacodynamic Properties of Metronidazole in Pediatric Patients With Acute Appendicitis: A Prospective Study. *J Pediatric Infect Dis Soc* 2019;8:297-302
687. Lee JY, Ally S, Kelly B, Kays D, Thames L. Once Daily Dosing of Ceftriaxone and Metronidazole in Children With Perforated Appendicitis. *The Journal of Pediatric Pharmacology and Therapeutics* 2016;21:140–145
688. Bowden CL, Janicak PG, Orsulak P et al. Relation of serum valproate concentration to response in mania. *The American Journal of Psychiatry* 1996;153:765-70
Chen J, Chan C, Colantonio D, Seto W. Therapeutic drug monitoring of voriconazole in children. *Ther Drug Monit.* 2012 Feb;34(1):77-84
689. Yip L, Aeng E, Elbe D. Management of acute agitation and aggression in children and adolescents with pro re nata oral immediate release antipsychotics in the pediatric emergency department. *J Child Adol Psychopharmacol* 2020;30:534-41
690. Nakamura Y, Takeuchi H, Okuyama K et al. Evaluation of appropriate blood level in continuous intravenous infusion from trough concentrations after oral administration based on area under trough level in tacrolimus and cyclosporine therapy. *Transplant Proc.* 2005 May;37:1725-7
691. SUBLOCADE® Buprenorphine extended-release injection. [Health Canada Product Monograph. Indivior UK Limited, Hull UK; Pharma Importing Inc. Toronto ON. Last revision: July 5 2022
692. Kutlu NO, Yakinci C, Dogrul M, et al. Intranasal midazolam for prolonged convulsive seizures. *Brain Devel* 2000;22:359-61
693. Riva A, Lapadre G, Grasso EA, et al. Intramuscular midazolam for treatment of status epilepticus. *Expert Opin Pharmacother* 2021;22(1)37-44